var title_f12_14_12512="Patient information: Carotid artery disease (The Basics)";
var content_f12_14_12512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Carotid artery disease (The Basics)",
"  </div>",
"  <a href=\"./authors-and-editors/patient-information\">",
"   Written by the doctors and editors at UpToDate",
"  </a>",
"  <br/>",
"  <br/>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 8, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25724324\">",
"    <span class=\"h1\">",
"     What is carotid artery disease?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid artery disease is a condition that can increase a person&rsquo;s risk of having a stroke. The condition does not usually cause symptoms. It happens when fatty deposits called plaque build up inside 2 blood vessels called the &ldquo;carotid arteries.&rdquo; These are the main blood vessels that bring blood to the brain. When plaque forms in these arteries, the arteries can become narrow (",
"    <a class=\"graphic graphic_figure graphicRef72617 \" href=\"UTD.htm?43/31/44533\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25724331\">",
"    <span class=\"h1\">",
"     What are the symptoms of carotid artery disease?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid artery disease does not usually cause symptoms. But it can cause strokes and TIAs (described below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Strokes",
"      </strong>",
"      &ndash; A stroke is when a part of the brain dies because it goes without blood and oxygen for too long. Carotid artery disease can lead to strokes, because blood clots can form inside the narrowed artery. Then the clots and other material from the fatty plaque can travel to the brain and clog smaller arteries.",
"      <br/>",
"      <br/>",
"      Some people recover from strokes without lasting effects or with only minor problems. But many people have serious problems after a stroke. After a stroke, some people are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Unable to speak or understand speech",
"     </li>",
"     <li>",
"      Paralyzed on one half of their body",
"     </li>",
"     <li>",
"      Unable to dress, feed, or take care of themselves",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       TIAs &ndash;",
"      </strong>",
"      TIA stands for &ldquo;transient ischemic attack.&rdquo; TIAs are basically strokes that last only a short time. But they do not cause brain damage. TIAs happen when a blood vessel in the brain gets clogged briefly and then reopens. People who have TIAs can have the symptoms of a stroke, but the symptoms go away in a short time. People who have TIAs are at very high risk of having a full-blown stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25724338\">",
"    <span class=\"h1\">",
"     Is there a test for carotid artery disease?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yes. Doctors can listen to each carotid artery with a stethoscope. They do this to check for a swishing sound that occurs when the artery is partly blocked. But to be sure, doctors also can use one of the following tests, which create pictures of the arteries:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Carotid duplex ultrasound",
"      </strong>",
"      &ndash; This test uses sound waves to create pictures.",
"     </li>",
"     <li>",
"      <strong>",
"       Magnetic resonance angiography (MRA)",
"      </strong>",
"      &ndash; This test uses a magnet to create pictures. It works the same way that MRI tests work. Before having MRA, most people get an injection of a chemical that makes the arteries show up more clearly.",
"     </li>",
"     <li>",
"      <strong>",
"       Computed tomography angiography (CTA)",
"      </strong>",
"      &ndash; This test uses a special kind of x-ray called a CT scan. Before having the scan, people get an injection of a chemical that makes the arteries show up more clearly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is another test that doctors sometimes use, called a &ldquo;cerebral angiogram.&rdquo; But that is not usually necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25724345\">",
"    <span class=\"h1\">",
"     How is carotid artery disease treated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments for carotid artery disease focus mostly on preventing stroke. Treatments can include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Lifestyle changes",
"      </strong>",
"      &ndash; People can reduce their risk of stroke by:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Quitting smoking if they smoke",
"     </li>",
"     <li>",
"      Being active",
"     </li>",
"     <li>",
"      Losing weight if they are overweight",
"     </li>",
"     <li>",
"      Eating a diet low in fat and cholesterol and high in fruits, vegetables, and low-fat dairy foods",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Medicines",
"      </strong>",
"      &ndash; Different people need different medicines to reduce their chances of having a stroke. In general, the medicines that can help prevent strokes include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Medicines to lower blood pressure",
"     </li>",
"     <li>",
"      Medicines called statins, which lower cholesterol",
"     </li>",
"     <li>",
"      Medicines to prevent blood clots, such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Surgery &ndash;",
"      </strong>",
"      Doctors can do surgery to remove plaque from the carotid arteries (",
"      <a class=\"graphic graphic_figure graphicRef52730 \" href=\"UTD.htm?33/45/34518\">",
"       figure 2",
"      </a>",
"      ). This is called &ldquo;carotid endarterectomy.&rdquo; This treatment is most appropriate for people who have had a TIA or stroke and who have a lot of plaque in their carotid arteries. It is also appropriate for some people who have not had a stroke or TIA but who have a lot of plaque in their carotid arteries.",
"     </li>",
"     <li>",
"      <strong>",
"       Carotid stenting &ndash;",
"      </strong>",
"      Carotid stenting is when doctors insert a tiny metal tube called a &ldquo;stent&rdquo; into the carotid artery. The stent is designed to prop open narrowed arteries. This treatment seems to be more dangerous than surgery, especially for people age 70 or older. It is not appropriate for most people.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25724352\">",
"    <span class=\"h1\">",
"     Which treatment is right for me?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The right treatment for you will depend on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whether you have already had a stroke or TIA that seemed to be caused by your carotid artery disease",
"     </li>",
"     <li>",
"      How much of your carotid artery is blocked off by plaque",
"     </li>",
"     <li>",
"      How old you are",
"     </li>",
"     <li>",
"      Whether you are a man or a woman",
"     </li>",
"     <li>",
"      Whether you have other health problems besides carotid artery disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If your doctor suggests surgery or stenting, ask these questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What are the chances that I will have a stroke in the next 5 years if I",
"      <strong>",
"       DO NOT",
"      </strong>",
"      have this procedure?",
"     </li>",
"     <li>",
"      What are the chances that I will have a stroke in the next 5 years if I",
"      <strong>",
"       DO",
"      </strong>",
"      have this procedure?",
"     </li>",
"     <li>",
"      What are the risks of the procedure?",
"     </li>",
"     <li>",
"      Does the surgeon who will do the procedure have a lot of experience?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25724432\">",
"    <span class=\"h1\">",
"     More on this topic",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"     Patient information: Stroke (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"     Patient information: High blood pressure in adults (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=see_link\">",
"     Patient information: High cholesterol (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=see_link\">",
"     Patient information: Doppler ultrasound (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=see_link\">",
"     Patient information: Vagal maneuvers and their responses (The Basics)",
"    </a>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15819 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-BE23660271-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12512=[""].join("\n");
var outline_f12_14_12512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25724324\">",
"      What is carotid artery disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25724331\">",
"      What are the symptoms of carotid artery disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25724338\">",
"      Is there a test for carotid artery disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25724345\">",
"      How is carotid artery disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25724352\">",
"      Which treatment is right for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25724432\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   GRAPHICS",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     FIGURES",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/31/44533\" title=\"figure 1\">",
"      Carotid plaques PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/45/34518\" title=\"figure 2\">",
"      Carotid endarterectomy PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=related_link\">",
"      Patient information: Doppler ultrasound (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=related_link\">",
"      Patient information: Vagal maneuvers and their responses (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_14_12513="Patient information: Polycythemia vera (PV) (The Basics)";
var content_f12_14_12513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/26/5537\">",
"         Patient information: Complete blood count (CBC) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Polycythemia vera (PV) (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H71624318\">",
"      <span class=\"h1\">",
"       What is polycythemia vera (PV)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Polycythemia vera (also called &ldquo;PV&rdquo;) is a condition that affects bone marrow, the tissue in the middle of your bones that makes blood cells.",
"     </p>",
"     <p>",
"      People with PV make too many red blood cells (the cells that carry oxygen to your body). They also have higher-than-normal levels of:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        White blood cells &ndash; These cells fight infections.",
"       </li>",
"       <li>",
"        Platelets &ndash; Platelets are actually pieces of cells, not whole cells. They help clots form so that you stop bleeding after you are injured.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H71624333\">",
"      <span class=\"h1\">",
"       What are the symptoms of PV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with PV might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have headaches",
"       </li>",
"       <li>",
"        Feel weak or dizzy",
"       </li>",
"       <li>",
"        Sweat a lot",
"       </li>",
"       <li>",
"        Feel very itchy, especially when rubbing their skin after a warm bath or shower",
"       </li>",
"       <li>",
"        Have painful, swollen joints, especially in the big toe, ankle, or knee (called &ldquo;gout&rdquo;)",
"       </li>",
"       <li>",
"        Have burning pain in the hands and feet, which can also turn red, white, or blue",
"       </li>",
"       <li>",
"        Have dangerous blood clots",
"       </li>",
"       <li>",
"        Have vision problems, such as seeing dark spots, sparks, or flashes",
"       </li>",
"       <li>",
"        Have stomach problems, such as pain in the upper belly",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H71624348\">",
"      <span class=\"h1\">",
"       Are there tests for PV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and order different blood tests. You might also need a test that uses sounds waves to take pictures inside your body, called an ultrasound. This test checks if your spleen is bigger than normal, which can happen in people with PV. The spleen is an organ in the upper left belly that controls the amount of blood in your body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H71624363\">",
"      <span class=\"h1\">",
"       How is PV treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Removing blood from your body (called &ldquo;phlebotomy&rdquo;) &ndash; This is similar to what happens if you give blood.",
"       </li>",
"       <li>",
"        Low-dose",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        &ndash; This helps prevent blood clots.",
"       </li>",
"       <li>",
"        Medicines to keep your bone marrow from making too many red blood cells - These include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?28/61/29653?source=see_link\">",
"         hydroxyurea",
"        </a>",
"        (brand names: Droxia, Hydrea) and interferon alpha (brand name: Intron A).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor might also prescribe medicines or other treatments to ease itching.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H71624378\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/26/5537?source=see_link\">",
"       Patient information: Complete blood count (CBC) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/14/12513?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86713 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12513=[""].join("\n");
var outline_f12_14_12513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71624318\">",
"      What is polycythemia vera (PV)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71624333\">",
"      What are the symptoms of PV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71624348\">",
"      Are there tests for PV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71624363\">",
"      How is PV treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71624378\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/26/5537?source=related_link\">",
"      Patient information: Complete blood count (CBC) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_14_12514="Liver disease in pregnancy";
var content_f12_14_12514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Clinical characteristics of liver diseases in pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 603px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PLTS: platelet count; PT: prothrombin time; AP: alkaline phosphatase; GGT: gammaglutamyl transpeptidase; WBC: white blood cell count; LDH: lactate dehydrogenase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; PP: Post partum.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12514=[""].join("\n");
var outline_f12_14_12514=null;
var title_f12_14_12515="Frameshift mutation";
var content_f12_14_12515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Frameshift mutation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: United States National Library of Medicine. Available online at: file://ghr.nlm.nih.gov/handbook/illustrations/frameshift (Accessed on 1/12/2009).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12515=[""].join("\n");
var outline_f12_14_12515=null;
var title_f12_14_12516="Parotid space anatomy";
var content_f12_14_12516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Parotid space anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12516=[""].join("\n");
var outline_f12_14_12516=null;
var title_f12_14_12517="Plasma cell vulvitis1";
var content_f12_14_12517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma cell vulvitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12517=[""].join("\n");
var outline_f12_14_12517=null;
var title_f12_14_12518="Furosemide: Patient drug information";
var content_f12_14_12518=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Furosemide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     see \"Furosemide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     see \"Furosemide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lasix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Furosemide&reg;;",
"     </li>",
"     <li>",
"      AVA-Furosemide;",
"     </li>",
"     <li>",
"      Bio-Furosemide;",
"     </li>",
"     <li>",
"      Dom-Furosemide;",
"     </li>",
"     <li>",
"      Furosemide Injection Sandoz Standard;",
"     </li>",
"     <li>",
"      Furosemide Injection, USP;",
"     </li>",
"     <li>",
"      Furosemide Special;",
"     </li>",
"     <li>",
"      Furosemide Special Injection;",
"     </li>",
"     <li>",
"      Lasix&reg;;",
"     </li>",
"     <li>",
"      Lasix&reg; Special;",
"     </li>",
"     <li>",
"      Novo-Semide;",
"     </li>",
"     <li>",
"      NTP-Furosemide;",
"     </li>",
"     <li>",
"      Nu-Furosemide;",
"     </li>",
"     <li>",
"      PMS-Furosemide;",
"     </li>",
"     <li>",
"      Teva-Furosemide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is a strong water pill. Sometimes too much water and major elements (potassium) in the blood may be lost. Your doctor will follow you closely to change the dose to match your body's needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to furosemide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need extra potassium. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hearing loss. This can be long-lasting.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea) with high doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699423",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) and tablets at room temperature. Do not freeze liquid (solution).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect liquid (solution) and tablets from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12503 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12518=[""].join("\n");
var outline_f12_14_12518=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174841\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174842\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019426\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019428\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019427\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019432\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019433\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019435\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019430\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019431\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019436\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019437\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=related_link\">",
"      Furosemide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=related_link\">",
"      Furosemide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_14_12519="Dysgerminoma histo";
var content_f12_14_12519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dysgerminoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The neoplastic germ cells have clear, glycogen-filled cytoplasm and central nuclei. Fibrous septa containing lymphocytes traverse the tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E MD and Farber JL MD. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy;1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12519=[""].join("\n");
var outline_f12_14_12519=null;
var title_f12_14_12520="Evaluation of thoracic and lumbar spinal column injury";
var content_f12_14_12520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of thoracic and lumbar spinal column injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/14/12520/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12520/contributors\">",
"     Amy Kaji, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12520/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/14/12520/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12520/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/14/12520/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12520/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/14/12520/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7762989\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less common than cervical spinal column injuries, injuries of the thoracolumbar spinal column can be devastating and are commonly associated with major injuries of the chest and abdomen following high-energy trauma. The evaluation of thoracic and lumbar spinal column injuries in adults is reviewed here.",
"   </p>",
"   <p>",
"    The evaluation and acute management of cervical spinal column injuries, spinal cord injuries, and spinal injuries in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41643764\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of spinal column injuries and the anatomy of the spinal column are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3417027\">",
"    <span class=\"h1\">",
"     MECHANISMS, CLASSIFICATION SCHEMES, AND TYPES OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common mechanisms of injury, classification schemes, and important types of thoracolumbar (TL) spinal column injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link&amp;anchor=H4#H4\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Mechanisms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link&amp;anchor=H23#H23\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Thoracic and lumbar (TL) spinal column injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3417233\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute management of spinal cord and spinal column injuries is discussed separately, as is the general management of the trauma patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\", section on 'Initial management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1101779\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with possible thoracolumbar spinal column injuries have often been involved in high-energy trauma (eg, motor vehicle collision) and sustained multiple injuries. Thus, the differential diagnosis for upper or lower back pain in these patients is broad. In addition to severe intrathoracic (eg, aortic injury), intraabdominal, and pelvic injuries, clinicians should consider spinal cord injury, spinal epidural hematoma, paraspinal hematoma, retroperitoneal hematoma and kidney injury, and soft tissue injuries. Diagnostic imaging must be obtained to differentiate among these entities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link\">",
"     \"Pelvic trauma: Initial evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=see_link\">",
"     \"Blunt genitourinary trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7763254\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1101561\">",
"    <span class=\"h2\">",
"     General guidelines and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once immediate, life-threatening conditions are addressed, a secondary survey of the trauma patient is performed to look closely for any sign of injury. In all cases of possible spinal injury, spinal immobilization must be maintained until the possibility of injury is excluded by clinical or radiographic means. General performance of the secondary survey is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link&amp;anchor=H1929825#H1929825\">",
"     \"Initial management of trauma in adults\", section on 'Secondary evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thoracolumbar (TL) fractures most commonly occur after motor vehicle collisions, a fall from a height, or penetrating trauma, including gunshot wounds. Many forces may be involved in TL fractures, including compression, flexion, extension, rotation, sheer, and distraction. However, the most common fracture mechanism is that of a compression fracture from an axial load. Age, female gender, and osteoporosis are considered major risk factors, as vertebral body compression fractures are more common in those with decreased bone density. Some malignancies have a propensity to metastasize to the spinal column (eg, lung, breast, prostate) and may lead to pathological fractures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link&amp;anchor=H4#H4\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13321950\">",
"    <span class=\"h2\">",
"     Spine immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most authorities advocate using a long board for performing spinal immobilization on trauma patients in the prehospital setting, there is considerable variation in technique [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/1\">",
"     1",
"    </a>",
"    ] and the length of time a patient remains on the board after arriving at the emergency department (ED) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/2\">",
"     2",
"    </a>",
"    ]. Many advocate that the long board only be used for extrication and transport to the hospital, and that it be removed promptly after the primary survey [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/3\">",
"     3",
"    </a>",
"    ]. We generally concur with this viewpoint.",
"   </p>",
"   <p>",
"    Prolonged immobilization on a spine board can lead to decubitus ulcers and contribute to respiratory compromise, and may not adequately immobilize the spine (eg, the gap often visible between the patient&rsquo;s back and the board clearly demonstrates the lack of lumbar support) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/2\">",
"     2",
"    </a>",
"    ]. However, rigorous outcome studies to determine the effect of spinal immobilization upon the mortality, neurological morbidity, and overall outcomes of trauma patients are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal technique for immobilizing the spine remains uncertain. Several techniques and a range of immobilization devices are used, including standard backboards, vacuum splints, and scoop stretchers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/5\">",
"     5",
"    </a>",
"    ]. In most instances, we use the following approach. Once the primary survey is completed, a patient being managed with spine immobilization is log-rolled onto their side while axial alignment is maintained. At least three people are needed to perform the log-roll properly. Next, a clinician inspects and palpates the entire length of the spine. If there is no sign of injury and no spinal tenderness, the backboard is removed. However, some clinicians prefer to continue immobilization with a long board until initial radiographs are obtained, provided these studies are not delayed. Note that some spine boards contain metal rods which may interfere with radiographs and should be replaced prior to imaging.",
"   </p>",
"   <p>",
"    If continued immobilization is deemed necessary (eg, due to radiographic abnormality, neurologic deficit, or high suspicion for spinal injury in an obtunded patient), the patient is carefully log-rolled while maintaining axial alignment, the spinal board is removed, and the patient is moved onto a firm mattress, generally using a sliding board [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/6\">",
"     6",
"    </a>",
"    ]. Often a slider board can be introduced at the same time the long board is removed, thereby minimizing patient motion. Nevertheless, the key, concept is that even the patient who warrants continued immobilization should be removed from the hard spinal board before complications, such as pressure sores or aspiration, occur. When there is no concomitant vertebral fracture, the incidence of isolated ligamentous injury of the thoracolumbar spine is low. If an injury of the cervical spine is known or suspected, a cervical collar should be kept in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1101568\">",
"    <span class=\"h2\">",
"     Clinical findings of TL spine injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;As part of the secondary survey, the entire back, chest, and abdomen should be inspected and palpated. Patients with major injuries to the chest, abdomen, or pelvis often sustain injuries to the thoracolumbar (TL) spine as well. Back pain and neurologic dysfunction are clinical findings associated with TL spinal column injuries.",
"   </p>",
"   <p>",
"    Depending upon the body habitus of the injured patient, the ability to palpate any deformity or step-off of the spine may be difficult, particularly in an uncooperative patient. A prospective observational study reported that clinical examination detected only 27 of 56 TL spine fractures among blunt trauma patients capable of being evaluated (sensitivity 48.2 percent, specificity 84.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/7\">",
"     7",
"    </a>",
"    ]. In this study, approximately two-thirds of the TL fractures sustained were of the transverse process. Advanced imaging of the involved region is warranted if the clinician detects focal tenderness, a neurologic deficit, or spinal deformity. (See",
"    <a class=\"local\" href=\"#H7762775\">",
"     'CT for thoracic and lumbar spinal column injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other signs suggestive of spinal column injury include contusions, abrasions, lacerations, open wounds, or muscle spasm in the general area of the spine. Any deviations from normal spinal curvature should be noted. Fractures can cause a kyphotic or scoliotic deformity; muscle spasms can cause a straightening of the spine and loss of lordosis. Note that the region of the spine between the T11 and L4 vertebrae is most susceptible to injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link&amp;anchor=H3#H3\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whenever feasible, a focused, but systematic neurologic evaluation should be performed in all patients with a possible TL spinal column injury. Ideally, this examination includes assessment of motor function, sensation, reflexes, and position sense. A significant portion of TL fractures damage the distal spinal cord or cauda equina to some degree [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/8-10\">",
"     8-10",
"    </a>",
"    ], and such injuries can present with lower extremity paresis, lower extremity or saddle anesthesia, or loss of bladder or anal sphincter function.",
"   </p>",
"   <p>",
"    Decreased rectal tone is thought to be a late finding of the cauda equina syndrome and is often absent immediately following an acute injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/11\">",
"     11",
"    </a>",
"    ]. Although previous iterations of Advanced Trauma Life Support advocated performing a digital rectal examination on all trauma patients during the secondary survey, there is no clear evidence that the examination is an accurate means for detecting spinal cord injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The neurologic examination and localization of spinal cord lesions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who sustain high-energy trauma, scapular contusions suggest a rotation or flexion-rotation injury of the thoracic spine. Close evaluation of the thoracic spine, generally including spinal reconstructions from a CT of the chest, is prudent in such cases. Large contusions in the lumbosacral area following trauma are associated with shear fractures in this region. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link&amp;anchor=H28#H28\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Translational spinal column injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classic presentation for a flexion-distraction injury (eg, Chance fracture) of the TL spine is that of a backseat passenger restrained by a lap belt only, without a shoulder strap [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/16\">",
"     16",
"    </a>",
"    ]. Such a patient may manifest ecchymosis on the lower abdomen and tenderness at the lumbar fracture site, but the absence of these signs does not preclude the diagnosis. Although neurologic deficits occur in fewer than 5 percent, patients with Chance fractures often sustain intraabdominal injury, such as intestinal perforation, hematoma, or contusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link&amp;anchor=H27#H27\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Flexion-distraction (lap belt) injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pelvis and lower extremities should be examined, paying particular attention to pelvic stability, signs of injury, and neurologic function. Approximately 10 percent of calcaneal fractures are associated with lumbar fractures when the mechanism of injury involves axial compression, such as a fall from a significant height [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link&amp;anchor=H18#H18\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Burst fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although performance of a careful physical examination remains important, the findings of several observational studies suggest that clinical examination alone is",
"    <strong>",
"     not",
"    </strong>",
"    sufficiently sensitive or specific to rule out or identify significant TL spine injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/7,18,19\">",
"     7,18,19",
"    </a>",
"    ]. According to a retrospective observational study of 536 blunt trauma patients with TL spine fractures, the absence of back pain or tenderness during a log-roll examination did not exclude a clinically significant thoracic fracture even among patients with a GCS of 15 who were not under the influence of alcohol and had not yet been treated with opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/19\">",
"     19",
"    </a>",
"    ]. Therefore, preliminary rules for determining the need for imaging in patients with possible TL spine trauma include the mechanism of injury and other factors, in addition to examination findings. (See",
"    <a class=\"local\" href=\"#H7762768\">",
"     'Decision rules for imaging thoracic or lumbar spine injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7762768\">",
"    <span class=\"h1\">",
"     DECISION RULES FOR IMAGING THORACIC OR LUMBAR SPINE INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to cervical spine trauma, few studies have been performed to develop decision rules for imaging potential thoracic and lumbar spine injuries. Researchers have identified potential predictors of thoracolumbar (TL) spine injuries based primarily upon review of retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/20-24\">",
"     20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential risk factors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal pain or tenderness over the TL spine",
"     </li>",
"     <li>",
"      Signs of injury (eg, bruising, hematoma) along the TL spine",
"     </li>",
"     <li>",
"      Neurologic deficit consistent with TL injury",
"     </li>",
"     <li>",
"      High-force mechanism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fall greater than 3 m (10 ft)",
"     </li>",
"     <li>",
"      Ejection from a vehicle",
"     </li>",
"     <li>",
"      Moderate or high-velocity motor vehicle collision",
"     </li>",
"     <li>",
"      Auto versus pedestrian",
"     </li>",
"     <li>",
"      Forceful direct blow (eg, struck with bat)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Painful distracting injury, particularly when elements of the mechanism or clinical evaluation suggest increased risk for TL injury. &nbsp;",
"     </li>",
"     <li>",
"      Presence of another spine injury, particularly a known cervical fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until better evidence is available to guide practice, we believe it is reasonable to obtain radiographic studies of the thoracic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lumbar spine when any one of these criteria exists. We concur with the general approach described in the Eastern Association for the Surgery of Trauma practice guidelines and believe that diagnostic imaging of the TL spine is generally not necessary in blunt trauma patients with a normal mental status and none of the risk factors described above [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of one vertebral fracture in a blunt trauma patient mandates radiographic evaluation of the entire spine, since there is a 5 to 15 percent risk of a second, noncontiguous fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/26\">",
"     26",
"    </a>",
"    ]. The association with a second fracture may be even higher in patients with cervical fractures. Using data from the National Trauma Database of the United States, a retrospective analysis that included over 30,000 patients with spine fractures following blunt trauma found the odds ratio of a thoracolumbar fracture to be two times higher in patients with a cervical spine fracture (OR 2.02; 95% CI 1.93-2.12) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/27\">",
"     27",
"    </a>",
"    ]. Among patients with a cervical spine fracture, 13.1 percent also had a thoracic or lumbar fracture, whereas among patients without a cervical spine fracture, 6.9 percent had a thoracolumbar fracture.",
"   </p>",
"   <p>",
"    Trauma patients with altered mental status may need imaging depending upon their level of alertness, examination findings, and clinical suspicion. Such patients are at higher risk of injury. Spinal immobilization is maintained until unstable injury is ruled out by clinical or radiographic evaluation.",
"   </p>",
"   <p>",
"    For patients with major trauma, high-risk features, or depressed mental status, multidetector computed tomography (MDCT) is the imaging modality of choice, used to assess the TL spine. In most instances, reconstructed images obtained from MDCT scans of the chest and abdomen performed as part of the patient's trauma evaluation can be used to assess the thoracic and lumbar (TL) spine. The use of reconstructed images reduces time, cost, and radiation exposure. A retrospective comparison of 72 patients who underwent both abdomino-pelvic MDCT and an additional thoracic-lumbar spine MDCT demonstrated no difference in fracture detection rates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AP and lateral plain x-rays of the thoracic and lumbar spine are generally sufficient to assess for the presence of injury in patients at lower risk. CT imaging is then obtained of areas with abnormal findings. Unfortunately, a review of 69 publications describing blunt injuries to the thoracolumbar spine failed to clearly define the criteria to determine who should get plain radiographs versus CT scans [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manual for Advanced Trauma Life Support&reg; describes a similar approach, recommending imaging for \"&hellip;any patient with an altered level of consciousness or cognitive dysfunction, GCS &lt;15, multi-system injuries, or a palpable gap or tenderness in the thoracolumbar area\" [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed decision rules demonstrate high sensitivity, but limited specificity. One group of researchers prospectively studied a cohort of 2404 patients undergoing TL spine radiographs following blunt trauma in order to assess six potential predictors of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complaints of TL spine pain",
"     </li>",
"     <li>",
"      TL spine tenderness",
"     </li>",
"     <li>",
"      Decreased level of consciousness",
"     </li>",
"     <li>",
"      Intoxication with alcohol or drugs",
"     </li>",
"     <li>",
"      Neurologic deficits",
"     </li>",
"     <li>",
"      Presence of a painful, distracting injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of any of the six predictors identified all 152 patients with TL fractures, demonstrating sensitivity of 100 percent (95% CI 98-100). However, the criteria demonstrated poor specificity (3.9 percent; 95% CI 3.1-4.8).",
"   </p>",
"   <p>",
"    Another group studied a potential decision rule for TL imaging by performing a chart review in which 100 subjects with TL spine fractures were compared with 100 randomly selected multi-trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/32\">",
"     32",
"    </a>",
"    ]. Radiographs were deemed necessary if the following criteria were met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant blunt multi-trauma (eg, trauma team activated), OR",
"     </li>",
"     <li>",
"      High-energy mechanism of injury (fall &gt;3 m [10 ft], moderate or high-velocity motor vehicle crash, motorcycle crash, or auto versus pedestrian),",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AND any of these high-risk criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GCS &lt;15",
"     </li>",
"     <li>",
"      Neurologic deficit",
"     </li>",
"     <li>",
"      Distracting injury",
"     </li>",
"     <li>",
"      Local signs of injury (eg, step-off, bruising, hematoma)",
"     </li>",
"     <li>",
"      Alcohol or drug intoxication",
"     </li>",
"     <li>",
"      Pain or tenderness over the spine",
"     </li>",
"     <li>",
"      Presence of another identified spine fracture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of any of the high-risk criteria predicted a TL injury with a sensitivity of 100 percent, a specificity of 11.3 percent, and a negative predictive value of 100 percent. The most sensitive criterion was the presence of back pain or midline tenderness (62.1 percent), while the most specific was the presence of a palpable step-off over the spine (100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7762775\">",
"    <span class=\"h1\">",
"     CT FOR THORACIC AND LUMBAR SPINAL COLUMN INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is more accurate than plain x-ray for diagnosing thoracolumbar (TL) spinal column injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/24,33-35\">",
"     24,33-35",
"    </a>",
"    ]. For patients who have sustained significant blunt TL trauma based upon mechanism or clinical findings and for obtunded patients, we suggest CT imaging be used to assess the TL spine. Reformatted images from standard CT studies of the chest and abdomen are preferred.",
"   </p>",
"   <p>",
"    Several studies support this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review found superior sensitivity and interobserver reliability in detecting TL spine injury with reformatted CT images compared with plain x-rays [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/36\">",
"       36",
"      </a>",
"      ]. Furthermore, CT did not require further patient transportation, radiation exposure, cost, or time when reformatted images were used.",
"     </li>",
"     <li>",
"      A prospective evaluation of 222 consecutive trauma patients requiring TL spine imaging because of clinical findings or altered mental status found the accuracy of helical CT for TL fractures to be 99 percent (95% CI 96-100) while the accuracy of plain radiographs was 87 percent (95% CI 82-92) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, images obtained from standard CT studies may be sufficient to assess for TL spine fractures. This was shown in an observational study in which 78 of 80 fractures of the TL spine were correctly identified using images from chest, abdomen, and pelvis CTs without reformatting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/38\">",
"     38",
"    </a>",
"    ]. Both missed injuries were minor fractures involving the transverse process in patients with multiple other spinal injuries.",
"   </p>",
"   <p>",
"    In contrast to the higher relative radiation exposure with cervical CT compared with plain x-ray, CT of the TL spine involves lower levels of radiation exposure compared with plain films (13 milliSieverts [mSv] versus 26 mSv) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analyses of cost effectiveness comparing CT to plain x-rays of the TL spine report that although CT has a higher initial fixed cost, this is offset by a reduced need for repeat radiographic examinations due to inadequate studies, lower medicolegal costs (including costs of prolonged hospitalizations, rehabilitation, lost productivity, and malpractice suits from missed injuries), and fixed personnel costs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigators have found that a CT obtained for the evaluation of chest and an abdominal injury provides sufficient data to screen for spinal fractures, thereby decreasing the time and cost of spine injury evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 3537 blunt trauma patients of whom 236 (7 percent) sustained a cervical, thoracic, or lumbar fracture, researchers found that CT identified 99.3 percent of all fractures. The one cervical and one thoracic fracture missed by CT required no or minimal (rigid cervical collar) treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A registry-based retrospective analysis of 573 trauma patients identified 54 who sustained spinal column injury and found CT to be 100 percent sensitive for detecting these injuries, compared with 70 percent sensitivity for plain x-ray [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24263064\">",
"    <span class=\"h1\">",
"     MRI FOR THORACIC AND LUMBAR SPINAL COLUMN INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic Resonance Imaging (MRI) can be used to evaluate the integrity of the spinal ligaments and surrounding soft tissues in a patient with spinal column trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/43\">",
"     43",
"    </a>",
"    ]. However, vertebral fractures are better characterized by CT, and MRI examination is often felt to be unnecessary for the management and treatment of specific fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/44\">",
"     44",
"    </a>",
"    ]. However, MRI is necessary to assess the spinal cord of any trauma patient with neurologic deficits or symptoms that suggest spinal cord injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link&amp;anchor=H17#H17\">",
"     \"Acute traumatic spinal cord injury\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7762960\">",
"    <span class=\"h1\">",
"     DEFINITIVE MANAGEMENT AND DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disposition of patients with spinal column injury depends primarily upon fracture stability and concomitant injuries. If a spinal column injury is deemed unstable, hospital admission and spine surgery consultation is mandatory. If consultation is not available onsite, immediate transfer must be arranged to a center that can provide these services. Patients with unstable fractures have commonly sustained multi-system trauma, and the extent of their other injuries determines whether they require admission to an intensive care unit or other monitored setting.",
"   </p>",
"   <p>",
"    Nonoperative management of thoracic and lumbar spinal fractures involves the use of a spinal orthotic vest or brace. The goals of operative and nonoperative surgical intervention in spinal column injuries are to decompress neural structures, stabilize unstable segments, and restore alignment of the vertebrae [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12520/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7762981\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injuries of the thoracolumbar (TL) spinal column are less common than cervical injuries, but can produce devastating neurologic injury. They are commonly associated with major injuries of the chest, abdomen,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pelvis following high-energy trauma. Motor vehicle crash is the most common cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link\">",
"       \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H1101779\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all cases of possible spinal column injury, spinal immobilization must be maintained until the possibility of injury is excluded by clinical or radiographic means. However, such patients may be removed from the hard long spine board onto a firm, flat mattress using the log-roll technique, as prolonged immobilization on the long board is associated with aspiration and pressure sores.",
"     </li>",
"     <li>",
"      Back pain, back deformity, and neurologic dysfunction are among the most common clinical findings associated with TL spinal column injuries. A significant portion of TL fractures damage the distal spinal cord or cauda equina to some degree, and such injuries can present with lower extremity paresis, lower extremity or saddle anesthesia, or loss of bladder or rectal continence. Other signs suggestive of injury include contusions, abrasions, lacerations, open wounds, or muscle spasm in the general area of the spine. (See",
"      <a class=\"local\" href=\"#H7763254\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective decision rules to determine the need for imaging in patients with possible TL spinal column injury await development. Until better evidence is available to guide practice, we believe it is reasonable to obtain radiographic studies of the thoracic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lumbar spine when any one of the following high-risk criteria exists:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Focal pain or tenderness over the TL spine",
"     </li>",
"     <li>",
"      Signs of injury (eg, step-off, bruising, hematoma) along the TL spine",
"     </li>",
"     <li>",
"      Neurologic deficit consistent with TL injury",
"     </li>",
"     <li>",
"      High-force mechanism (fall greater than 3 m (10 ft); ejection from a vehicle; moderate or high-velocity motor vehicle crash; auto versus pedestrian)",
"     </li>",
"     <li>",
"      Painful distracting injury (particularly when elements of the mechanism or clinical evaluation suggest increased risk for TL injury)",
"     </li>",
"     <li>",
"      Presence of another spine injury, particularly a cervical spine fracture (see",
"      <a class=\"local\" href=\"#H7762768\">",
"       'Decision rules for imaging thoracic or lumbar spine injury'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with major trauma, high-risk features, or depressed mental status, CT is used to assess the TL spine. When available, reconstructed images obtained from multidetector CT scans of the chest, abdomen, and pelvis performed as part of the patient's general trauma evaluation should be used. AP and lateral plain x-rays of the thoracic and lumbar spine are generally sufficient to assess for the presence of injury in patients at lower risk. CT imaging is then obtained of areas with abnormal findings. (See",
"      <a class=\"local\" href=\"#H7762775\">",
"       'CT for thoracic and lumbar spinal column injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4425123\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/1\">",
"      Malik MH, Lovell ME. Current spinal board usage in emergency departments across the UK. Injury 2003; 34:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/2\">",
"      Vickery D. The use of the spinal board after the pre-hospital phase of trauma management. Emerg Med J 2001; 18:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/3\">",
"      Stagg MJ, Lovell ME. A repeat audit of spinal board usage in the emergency department. Injury 2008; 39:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/4\">",
"      Kwan I, Bunn F, Roberts I. Spinal immobilisation for trauma patients. Cochrane Database Syst Rev 2001; :CD002803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/5\">",
"      Hauswald M, Hsu M, Stockoff C. Maximizing comfort and minimizing ischemia: a comparison of four methods of spinal immobilization. Prehosp Emerg Care 2000; 4:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/6\">",
"      Hauswald M, Braude D. Spinal immobilization in trauma patients: is it really necessary? Curr Opin Crit Care 2002; 8:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/7\">",
"      Inaba K, DuBose JJ, Barmparas G, et al. Clinical examination is insufficient to rule out thoracolumbar spine injuries. J Trauma 2011; 70:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/8\">",
"      Meves R, Avanzi O. Correlation between neurological deficit and spinal canal compromise in 198 patients with thoracolumbar and lumbar fractures. Spine (Phila Pa 1976) 2005; 30:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/9\">",
"      Denis F, Armstrong GW, Searls K, Matta L. Acute thoracolumbar burst fractures in the absence of neurologic deficit. A comparison between operative and nonoperative treatment. Clin Orthop Relat Res 1984; :142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/10\">",
"      McDonough PW, Davis R, Tribus C, Zdeblick TA. The management of acute thoracolumbar burst fractures with anterior corpectomy and Z-plate fixation. Spine (Phila Pa 1976) 2004; 29:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/11\">",
"      Spector LR, Madigan L, Rhyne A, et al. Cauda equina syndrome. J Am Acad Orthop Surg 2008; 16:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/12\">",
"      Esposito TJ, Ingraham A, Luchette FA, et al. Reasons to omit digital rectal exam in trauma patients: no fingers, no rectum, no useful additional information. J Trauma 2005; 59:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/13\">",
"      Porter JM, Ursic CM. Digital rectal examination for trauma: does every patient need one? Am Surg 2001; 67:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/14\">",
"      Shlamovitz GZ, Mower WR, Bergman J, et al. Poor test characteristics for the digital rectal examination in trauma patients. Ann Emerg Med 2007; 50:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/15\">",
"      Guldner GT, Brzenski AB. The sensitivity and specificity of the digital rectal examination for detecting spinal cord injury in adult patients with blunt trauma. Am J Emerg Med 2006; 24:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/16\">",
"      Gordon ZL, Gillespie RJ, Ponsky TA, et al. Three siblings with Chance fractures: the importance of 3-point restraints. J Pediatr Orthop 2009; 29:856.",
"     </a>",
"    </li>",
"    <li>",
"     Keene, GS, Edwards, DJ, Robinson, AHN, Bowditch, MG. Key topics in orthopaedic trauma surgery, Bios Scientific, Oxford 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/18\">",
"      Sava J, Williams MD, Kennedy S, Wang D. Thoracolumbar fracture in blunt trauma: is clinical exam enough for awake patients? J Trauma 2006; 61:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/19\">",
"      Gill DS, Mitra B, Reeves F, et al. Can initial clinical assessment exclude thoracolumbar vertebral injury? Emerg Med J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/20\">",
"      Cooper C, Dunham CM, Rodriguez A. Falls and major injuries are risk factors for thoracolumbar fractures: cognitive impairment and multiple injuries impede the detection of back pain and tenderness. J Trauma 1995; 38:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/21\">",
"      Frankel HL, Rozycki GS, Ochsner MG, et al. Indications for obtaining surveillance thoracic and lumbar spine radiographs. J Trauma 1994; 37:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/22\">",
"      Durham RM, Luchtefeld WB, Wibbenmeyer L, et al. Evaluation of the thoracic and lumbar spine after blunt trauma. Am J Surg 1995; 170:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/23\">",
"      Meldon SW, Moettus LN. Thoracolumbar spine fractures: clinical presentation and the effect of altered sensorium and major injury. J Trauma 1995; 39:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/24\">",
"      Sixta S, Moore FO, Ditillo MF, et al. Screening for thoracolumbar spinal injuries in blunt trauma: an Eastern Association for the Surgery of Trauma practice management guideline. J Trauma Acute Care Surg 2012; 73:S326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/25\">",
"      O'Connor E, Walsham J. Review article: indications for thoracolumbar imaging in blunt trauma patients: a review of current literature. Emerg Med Australas 2009; 21:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/26\">",
"      Holmes JF, Miller PQ, Panacek EA, et al. Epidemiology of thoracolumbar spine injury in blunt trauma. Acad Emerg Med 2001; 8:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/27\">",
"      Winslow JE 3rd, Hensberry R, Bozeman WP, et al. Risk of thoracolumbar fractures doubled in victims of motor vehicle collisions with cervical spine fractures. J Trauma 2006; 61:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/28\">",
"      Kim S, Yoon CS, Ryu JA, et al. A comparison of the diagnostic performances of visceral organ-targeted versus spine-targeted protocols for the evaluation of spinal fractures using sixteen-channel multidetector row computed tomography: is additional spine-targeted computed tomography necessary to evaluate thoracolumbar spinal fractures in blunt trauma victims? J Trauma 2010; 69:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/29\">",
"      Diaz JJ Jr, Cullinane DC, Altman DT, et al. Practice management guidelines for the screening of thoracolumbar spine fracture. J Trauma 2007; 63:709.",
"     </a>",
"    </li>",
"    <li>",
"     Advanced trauma life support student course manual, 7th ed, American College of Surgeons 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/31\">",
"      Holmes JF, Panacek EA, Miller PQ, et al. Prospective evaluation of criteria for obtaining thoracolumbar radiographs in trauma patients. J Emerg Med 2003; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/32\">",
"      Hsu JM, Joseph T, Ellis AM. Thoracolumbar fracture in blunt trauma patients: guidelines for diagnosis and imaging. Injury 2003; 34:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/33\">",
"      Brandt MM, Wahl WL, Yeom K, et al. Computed tomographic scanning reduces cost and time of complete spine evaluation. J Trauma 2004; 56:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/34\">",
"      Rhee PM, Bridgeman A, Acosta JA, et al. Lumbar fractures in adult blunt trauma: axial and single-slice helical abdominal and pelvic computed tomographic scans versus portable plain films. J Trauma 2002; 53:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/35\">",
"      Gestring ML, Gracias VH, Feliciano MA, et al. Evaluation of the lower spine after blunt trauma using abdominal computed tomographic scanning supplemented with lateral scanograms. J Trauma 2002; 53:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/36\">",
"      Inaba K, Munera F, McKenney M, et al. Visceral torso computed tomography for clearance of the thoracolumbar spine in trauma: a review of the literature. J Trauma 2006; 60:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/37\">",
"      Hauser CJ, Visvikis G, Hinrichs C, et al. Prospective validation of computed tomographic screening of the thoracolumbar spine in trauma. J Trauma 2003; 55:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/38\">",
"      Mancini DJ, Burchard KW, Pekala JS. Optimal thoracic and lumbar spine imaging for trauma: are thoracic and lumbar spine reformats always indicated? J Trauma 2010; 69:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/39\">",
"      Antevil JL, Sise MJ, Sack DI, et al. Spiral computed tomography for the initial evaluation of spine trauma: A new standard of care? J Trauma 2006; 61:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/40\">",
"      Blackmore CC, Ramsey SD, Mann FA, Deyo RA. Cervical spine screening with CT in trauma patients: a cost-effectiveness analysis. Radiology 1999; 212:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/41\">",
"      Grogan EL, Morris JA Jr, Dittus RS, et al. Cervical spine evaluation in urban trauma centers: lowering institutional costs and complications through helical CT scan. J Am Coll Surg 2005; 200:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/42\">",
"      Brown CV, Antevil JL, Sise MJ, Sack DI. Spiral computed tomography for the diagnosis of cervical, thoracic, and lumbar spine fractures: its time has come. J Trauma 2005; 58:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/43\">",
"      Goldberg AL, Kershah SM. Advances in imaging of vertebral and spinal cord injury. J Spinal Cord Med 2010; 33:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/44\">",
"      Dai LY, Ding WG, Wang XY, et al. Assessment of ligamentous injury in patients with thoracolumbar burst fractures using MRI. J Trauma 2009; 66:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12520/abstract/45\">",
"      Siebenga J, Leferink VJ, Segers MJ, et al. Treatment of traumatic thoracolumbar spine fractures: a multicenter prospective randomized study of operative versus nonsurgical treatment. Spine (Phila Pa 1976) 2006; 31:2881.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15849 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-C266496ECC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12520=[""].join("\n");
var outline_f12_14_12520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7762981\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7762989\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41643764\">",
"      EPIDEMIOLOGY AND ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3417027\">",
"      MECHANISMS, CLASSIFICATION SCHEMES, AND TYPES OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3417233\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1101779\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7763254\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1101561\">",
"      General guidelines and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13321950\">",
"      Spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1101568\">",
"      Clinical findings of TL spine injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7762768\">",
"      DECISION RULES FOR IMAGING THORACIC OR LUMBAR SPINE INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7762775\">",
"      CT FOR THORACIC AND LUMBAR SPINAL COLUMN INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24263064\">",
"      MRI FOR THORACIC AND LUMBAR SPINAL COLUMN INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7762960\">",
"      DEFINITIVE MANAGEMENT AND DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7762981\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4425123\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=related_link\">",
"      Blunt genitourinary trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=related_link\">",
"      Evaluation and acute management of cervical spinal column injuries in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=related_link\">",
"      Pelvic trauma: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=related_link\">",
"      Spinal column injuries in adults: Definitions, mechanisms, and radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_14_12521="Principles of grafts and flaps for reconstructive surgery";
var content_f12_14_12521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of grafts and flaps for reconstructive surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/14/12521/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12521/contributors\">",
"     Donald Morris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/14/12521/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12521/contributors\">",
"     Charles E Butler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/14/12521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12521/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/14/12521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H713392042\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine use of grafts and flaps has dramatically broadened the ability of the surgeon to perform reconstructive surgery and improve outcomes and quality of life for trauma patients, burn patients, and cancer patients.",
"   </p>",
"   <p>",
"    This topic provides an overview of the use of grafts and flaps in reconstructive surgery. Reconstructive surgical procedures for specific clinical problems are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link\">",
"       Breast reconstruction in women with breast cancer",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=see_link\">",
"       Mandibular and palatal reconstruction in patients with head and neck cancer",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link\">",
"       Principles of burn reconstruction: Overview of surgical procedures",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713392049\">",
"    <span class=\"h1\">",
"     SKIN GRAFTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A skin graft is the transfer of skin from a donor site to a recipient site. The transplanted skin does not have a blood supply and initially survives by absorbing transudate from the recipient site, a process called plasmatic imbibition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/1\">",
"     1",
"    </a>",
"    ]. Neovascularization from the graft bed capillaries then provides a blood supply to the graft over the next 48 to 72 hours. Full circulation is restored within four to seven days.",
"   </p>",
"   <p>",
"    In contrast to a skin graft, a flap carries its own blood supply and is therefore not dependent on the recipient bed to revascularize the tissue. Flaps are discussed below (see",
"    <a class=\"local\" href=\"#H713392070\">",
"     'Flaps'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632143838\">",
"    <span class=\"h2\">",
"     Indications for skin grafting",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin grafts are indicated for coverage of a skin defect due to trauma, burns, or excision of a tumor if closure cannot be accomplished by approximating the edges of the wound. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link\">",
"       \"Closure of skin wounds with sutures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin grafts can also be used to provide coverage for and more rapid healing of leg ulcers after debridement if the bed of the wound is well vascularized. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37064?source=see_link&amp;anchor=H18#H18\">",
"       \"Treatment of pressure ulcers\", section on 'Surgery for wound closure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H55268712#H55268712\">",
"       \"Basic principles of wound management\", section on 'Wound debridement'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301311054\">",
"    <span class=\"h2\">",
"     Types of skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;A skin graft can be partial or full thickness:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713392056\">",
"    <span class=\"h3\">",
"     Split thickness skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Split thickness skin grafts (STSG), also called partial thickness grafts, transfer a portion of the donor site skin including the epidermis and some of the underlying dermis. This allows the donor site to heal from the epidermal elements left behind. STSG can be utilized as an intact sheet or expanded via a mechanical mesher device (",
"    <a class=\"graphic graphic_picture graphicRef77019 \" href=\"UTD.htm?33/63/34802\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57087 \" href=\"UTD.htm?39/0/39937\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63714 \" href=\"UTD.htm?7/6/7265\">",
"     picture 3",
"    </a>",
"    ). Meshing of a graft increases the surface area that can be covered by a graft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713392063\">",
"    <span class=\"h3\">",
"     Full thickness skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Full thickness skin grafts (FTSG) harvest the entire layer of skin as the graft. Thus, no dermal or epidermal elements remain at the donor site, which must be closed by local advancement of the adjoining skin or by a secondary local flap. The process of revascularization takes longer for a full thickness graft than for a split thickness skin graft because of the increased thickness of the tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301311091\">",
"    <span class=\"h2\">",
"     Choice of split versus full thickness grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to take into account the role of wound contraction in the decision to use a partial versus a FTSG [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/2\">",
"     2",
"    </a>",
"    ]. In general, the degree of contraction is less when a graft is thicker, and minimal wound contraction occurs with full thickness skin grafts. However, with a thicker graft, more tissue revascularization is required [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients requiring grafts on the face, a FTSG is preferable because of the aesthetic benefits of minimal contraction.",
"     </li>",
"     <li>",
"      In patients who have large defects of the trunk or extremities away from joints, a STSG is preferable because wound contraction results in a smaller area of scarring.",
"     </li>",
"     <li>",
"      In patients requiring grafts over areas of mobility (joints) or functionally crucial areas (finger tips), FTSG are preferable because of the functional benefits of minimal contraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301310968\">",
"    <span class=\"h2\">",
"     Surgical technique for skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor site selection and recipient site preparation are similar for STSG and FTSG. However, they are harvested by different methods and the donor sites are treated differently after harvest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192764524\">",
"    <span class=\"h3\">",
"     Donor site selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The donor site is selected to minimize discomfort and cosmetic issues at the donor site, while maximizing the outcome at the recipient site. The choice of donor sites depends on the desired color, texture, and thickness of the skin at the recipient site. The quality of the donor site skin should also be evaluated for evidence of prior sun damage (eg, keratoses) and prior scarring. Donor sites should be inconspicuous areas with loose skin that allows for primary repair. Donor site morbidity is limited to a scar at the site of the harvest.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On the face, it is desirable to replace \"like with like\" and utilize skin as close to the recipient site as possible. For example, nasal tip grafts are often best taken from the preauricular skin rather than the supracervical skin as the color and thickness match are better.",
"     </li>",
"     <li>",
"      An open wound of the trunk can be grafted from almost any donor site as the skin color and texture are not important. The upper lateral thigh is a good choice for an area on the trunk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192764531\">",
"    <span class=\"h3\">",
"     Recipient site preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper preparation of the recipient site is crucial for both split thickness and full thickness skin grafts. The recipient site must be well vascularized, as evidenced by the presence of granulation tissue. Surgically created wounds are designed to leave a well vascularized bed so no special preparation is required. Acute traumatic wounds often have a healthy bed, once injured and devascularized tissue is removed. More chronic wounds may take a period of dressing changes to promote neovascularization in the bed.",
"   </p>",
"   <p>",
"    The wound bed must be free of all necrotic or ischemic tissue, cellulitis, purulent drainage, and significant edema. Granulation tissue can be heavily colonized and should be gently debrided back to the wound base. The recipient site should be thoroughly irrigated prior to graft placement. One approach is to use pulsatile jet lavage with a triple antibiotic solution (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    , polymyxin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    ) to reduce bacterial contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/4\">",
"     4",
"    </a>",
"    ]. If the base is bony or tendinous, a graft may not take and a flap may be needed instead (see",
"    <a class=\"local\" href=\"#H1933995\">",
"     'Indications for flap coverage'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Skin margins should be trimmed to expose healthy, unscarred dermis. Hemostasis must be meticulous to prevent blood or fluid collections from accumulating beneath the graft because these are a common cause of graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516241821\">",
"    <span class=\"h3\">",
"     STSG technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Harvest",
"      </strong>",
"      &ndash; STSG are harvested using a mechanical dermatome, which is a device with a large scalpel-like blade and an adjustable depth gauge. Dermatomes are usually powered by compressed air or electricity, though manual dermatomes are available [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/6\">",
"       6",
"      </a>",
"      ]. Most split thickness grafts are harvested 16 to",
"      <span class=\"nowrap\">",
"       18/1000",
"      </span>",
"      of an inch thick. To harvest the skin, the donor site is put on tension by the assistant after the surface of both the dermatome and the skin has been lubricated with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       mineral oil",
"      </a>",
"      or surgical water based lubricant. The dermatome is engaged on the skin surface at an angle of approximately 30 degrees and gently pushed forward while exerting a modest amount of downward pressure on the dermatome. The partial thickness skin will come off the blade as the dermatome is moved forward. At the completion of the harvest, the dermatome is lifted, which usually severs the graft. If the graft does not come completely off the donor site, a scalpel is used to complete the final cut. The graft is then either transferred to the recipient site or meshed prior to transfer.",
"     </li>",
"     <li>",
"      <strong>",
"       Graft meshing",
"      </strong>",
"      &ndash; Mechanical skin graft meshers are available which increase the surface area that a graft will cover. The meshing process can be done with varied expansion ratios ranging from 1.5:1 up to 9:1. The larger mesh ratios are reserved for patients with limited donor sites such as major burn patients. The smaller mesh ratios allow for limiting donor site scarring and offer improved drainage through the graft, thereby limiting subgraft fluid accumulation. Fluid accumulation beneath any type of skin graft can hinder the revascularization process. Fluid can freely drain out the interstices (ie, openings) of a meshed graft, which improves graft take.",
"      <br/>",
"      <br/>",
"      Meshed grafts offer the opportunity for surface area expansion, which is particularly important in larger area burn victims, where donor sites are precious. However, meshed grafts heal with more scarring due to the secondary healing of the interstices and are therefore less aesthetically appealing than sheet (unmeshed) skin grafts. Accordingly, mesh grafting is reserved for areas where the aesthetic result is not a concern (",
"      <a class=\"graphic graphic_picture graphicRef70840 \" href=\"UTD.htm?34/59/35765\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef69982 \" href=\"UTD.htm?0/17/274\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Graft inset",
"      </strong>",
"      &ndash; STSG are transferred dermis-side-down to the recipient site and sutured into place with fine absorbable sutures. If the wound has an unusual surface contour, multiple tacking sutures can also be applied over the course of the graft to the underlying wound bed. For small STSG, natural (eg, fibrin) or synthetic (eg, cyanoacrylate) glue can be used to secure a graft instead of suture [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. There are no randomized trials comparing glue to suture for STSG. However, glue has been used successfully for graft inset in several case series. As an example, in a series of 15 patients with 17 lower extremity ulcers, fibrin glue was used instead of suture to secure STSG [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/9\">",
"       9",
"      </a>",
"      ]. Most of the skin grafts",
"      <span class=\"nowrap\">",
"       (13/17)",
"      </span>",
"      healed successfully.",
"     </li>",
"     <li>",
"      <strong>",
"       Recipient site care",
"      </strong>",
"      &ndash; Immobilization of the graft to the recipient bed is imperative to prevent shearing of the graft",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      accumulation of fluid under the graft, which would prevent the process of neovascularization from occurring, thus causing skin graft failure. Meshed grafts drain underlying wound fluid through the interstices, but still need to be immobilized to facilitate healing.",
"      <br/>",
"      <br/>",
"      Bolster dressings have long been utilized to stabilize grafts. A bolster dressing can be sewn in place to cover the graft and hold it in place. This is done by placing stitches around the periphery of the graft and leaving them long enough to tie together over the bolster, which is usually a ball of sterile cotton.",
"      <br/>",
"      <br/>",
"      Negative pressure wound therapy (eg, vacuum-assisted closure device or VAC&trade; therapy) provides another method of graft immobilization (",
"      <a class=\"graphic graphic_figure graphicRef50588 \" href=\"UTD.htm?23/21/23889\">",
"       figure 2",
"      </a>",
"      ). &nbsp;This technique minimizes shearing and subgraft fluid accumulation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/10\">",
"       10",
"      </a>",
"      ]. The device is usually left in place for 5 to 10 days after graft placement. If the graft is being applied near a joint, elevation and a splint may also be necessary to decrease swelling and ensure immobilization during the healing period. In addition, all extremities that are grafted should be elevated for a number of days to decrease postoperative edema. After removal of the bandages, the graft will be dry, and a gentle daily application of moisturizer is helpful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link&amp;anchor=H17#H17\">",
"       \"Negative pressure wound therapy\", section on 'Skin graft/flap fixation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Donor site care",
"      </strong>",
"      &ndash; A bismuth impregnated petrolatum gauze dressing is used (eg, Xeroform",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) to cover the donor site. This allows for easier removal of the overlying dry gauze dressing. The donor site, with the gauze in place, is then opened to air 12 to 24 hours post harvest to allow for drying of the gauze, which then becomes adherent to the donor site. As the wound reepithelializes underneath, the gauze will separate, usually falling off the wound by 7 to 14 days. Once the dressing is off, the patient should moisturize the donor site daily as the skin will be dry for a period of time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H451034789\">",
"    <span class=\"h3\">",
"     FTSG technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Harvest",
"      </strong>",
"      &ndash; FTSG are most commonly harvested manually. A template of",
"      <sup>",
"      </sup>",
"      the defect should be made using a flexible material which can conform to the defect. This allows for a \"tailor made\" fit for the harvested skin, without removing more skin than is required. The incision is made with a scalpel, and sharp dissection of the full thickness of skin is done, removing all subcutaneous elements. The use of electrocautery during graft harvest should be minimized so as to not cause thermal damage to the graft.",
"     </li>",
"     <li>",
"      <strong>",
"       Graft inset",
"      </strong>",
"      &ndash; FTSG grafts must be inset meticulously and sutured into place with fine absorbable sutures to a bed that has thorough hemostasis. These grafts will contract very little as they heal, thus inset should be tailored to fit the size and shape of the defect.",
"     </li>",
"     <li>",
"      <strong>",
"       Donor site care",
"      </strong>",
"      &ndash; Primary suture repair of the donor site is performed and a simple dressing is applied. Wounds should be closed along natural skin creases (relaxed skin tension lines or Langer&rsquo;s lines), particularly in the face (",
"      <a class=\"graphic graphic_figure graphicRef57566 \" href=\"UTD.htm?9/21/9558\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50913 \" href=\"UTD.htm?32/4/32837\">",
"       figure 4",
"      </a>",
"      ). Violating these lines leads to more visible scars. Tension in a skin closure can lead to unsightly hypertrophic scarring.",
"     </li>",
"     <li>",
"      <strong>",
"       Recipient site care",
"      </strong>",
"      &ndash; Immobilization of the graft to the recipient bed is required to prevent shearing of the graft",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      accumulation of fluid under the graft, which would prevent the process of neovascularization from occurring, thus causing skin graft failure. Graft immobilization is crucial with a FTSG as no mesh interstices exist to allow for fluid drainage. Bolster dressings or a negative pressure wound therapy device can be utilized to ensure immobilization of the healing graft (see",
"      <a class=\"local\" href=\"#H516241821\">",
"       'STSG technique'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632143769\">",
"    <span class=\"h2\">",
"     Graft maturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It takes a graft from three to six months to mature. Initially a graft is erythematous and irregular. Over time, the graft will smooth out but will retain the color and consistency of the donor site, which is a major shortcoming of a skin graft. A local flap will provide a better aesthetic result than a graft because it allows replacement of &ldquo;like with like&rdquo; (see",
"    <a class=\"local\" href=\"#H713392252\">",
"     'Local flaps'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The donor site of a STSG remains hyperpigmented for a number of months before returning to normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632143779\">",
"    <span class=\"h2\">",
"     Graft failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft failure can result from insufficient vascularity of the recipient site, hematoma, seroma, infection, excessive tension, or mechanical shearing forces. Proper preparation of the wound bed, meticulous hemostasis, careful inset of the graft, and proper dressing along with immobilization during the healing period can help avoid most of these complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comorbidities including diabetes, smoking, protein or vitamin deficiencies can affect vascularity and wound healing. In addition, medications such as steroids, immunosuppressive medications, and anticoagulants can interfere with wound healing. These are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5177?source=see_link&amp;anchor=H1070222581#H1070222581\">",
"     \"Wound healing and risk factors for non-healing\", section on 'Risk factors for non-healing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection is most commonly due to methicillin-resistant coagulase-positive staphylococci (MRSA), beta-hemolytic streptococci, or pseudomonas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/1\">",
"     1",
"    </a>",
"    ]. Cultures should be obtained to direct antibiotic treatment. Empiric treatment of infection is based on whether there is purulent drainage. Options for empiric therapy for purulent and nonpurulent cellulitis are outlined in the attached tables and discussed elsewhere (",
"    <a class=\"graphic graphic_table graphicRef64178 \" href=\"UTD.htm?9/57/10140\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64128 \" href=\"UTD.htm?23/12/23756\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link&amp;anchor=H8#H8\">",
"     \"Cellulitis and erysipelas\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Partial graft loss can be treated with wet to moist saline soaked gauze or other local dressings and usually will heal secondarily. Complete graft loss requires reassessment of the bed. When the wound bed is well vascularized, then regrafting can be attempted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H55268776#H55268776\">",
"     \"Basic principles of wound management\", section on 'Wound dressings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713392070\">",
"    <span class=\"h1\">",
"     FLAPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A flap is a transfer of skin, underlying tissue, and blood supply from one part of the body to another. Unlike grafts, flaps are not dependent on the recipient bed for vascularization. Thus, the volume of transferred tissue can be significantly greater than that of a skin graft and can contain multiple types of tissue, including skin, muscle, nerve, fascia, and bone. This volume of tissue requires constant vascular supply and is at risk of vascular compromise if the arterial supply or venous drainage is compromised during or following transfer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1933995\">",
"    <span class=\"h2\">",
"     Indications for flap coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A flap is the best approach to wound repair when primary repair is unobtainable without undue tension, the wound bed is not amenable to grafting because the defect is not well vascularized, such as those with exposed bone or tendon. Flaps are also the best approach for defect coverage when the aesthetics are unfavorable for grafting because a larger or more complex piece of tissue is required to regain normal appearance (eg, breast reconstruction).",
"   </p>",
"   <p>",
"    Flaps have broad applicability and choice with an almost endless array of flaps available to cover even the most complex defects. Aesthetic and functional results need to be taken into account as do comorbidities and donor site morbidity. The defect location, size, and functional requirements and exposure of any crucial structures should all be considered. In addition, evaluation of the bed of the wound is important. As an example, if the area has been subjected to radiation therapy, the wound is more susceptible to dehiscence and infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link\">",
"     \"Basic principles of wound management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5177?source=see_link\">",
"     \"Wound healing and risk factors for non-healing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice and design of the flap depend on the size and location of the wound bed, as well as aesthetic and functional issues. In addition, tendon, bone, and vessel exposure must be taken into account.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Facial skin defects are best closed with local flaps, utilizing similar tissue transferred as a random pattern transposition or rotational flap. Examples include local rhomboid flaps and V-Y advancement flaps (",
"      <a class=\"graphic graphic_figure graphicRef77521 \" href=\"UTD.htm?1/8/1152\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56528 \" href=\"UTD.htm?34/54/35680\">",
"       figure 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef65751 \" href=\"UTD.htm?14/3/14399\">",
"       figure 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Truncal defects are less dependent on aesthetics and usually require a larger volume of tissue to be transferred.",
"     </li>",
"     <li>",
"      Specialized areas such as the hands and feet require special consideration when selecting flap closure. The palmar and plantar skin is unique and difficult to replace. Most areas of the hands and feet require thin flaps in order to obtain the best functional results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301310853\">",
"    <span class=\"h2\">",
"     Blood supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood supply to a flap can be random or axial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Random blood supply",
"      </strong>",
"      &ndash; The blood supply to the flap is provided by many little unnamed vessels of the subdermal plexus.",
"     </li>",
"     <li>",
"      <strong>",
"       Axial blood supply",
"      </strong>",
"      &ndash; The blood supply to the flap is provided by a recognized (named) artery or group of arteries. Regional areas that are supplied by individual named blood vessels are termed \"angiosomes\". Most flaps will survive if the tissue transferred contains the vessels that supply the angiosomes and an additional neighboring vascular territory. The concept of angiosomes has revolutionized flap design, adding anatomic understanding to prior clinical experience [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/13-15\">",
"       13-15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713392231\">",
"    <span class=\"h2\">",
"     Site preparation for flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of site preparation for flap coverage are similar to those for skin grafts. The wound must be free",
"    <strong>",
"    </strong>",
"    of all necrotic or ischemic tissue, infection, and significant edema. However, as the flap carries its own blood supply, the wound bed need not be well vascularized (see",
"    <a class=\"local\" href=\"#H192764531\">",
"     'Recipient site preparation'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713392245\">",
"    <span class=\"h2\">",
"     Flap choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flap selection begins with an analysis of the defect, including the location and condition of the defect bed, comorbidities (eg, cigarette abuse, history of radiation therapy), cosmetic significance, and functional significance. In addition to evaluating the defect to be closed, the surgeon must consider the donor site morbidity, including scarring and functional loss if the flap includes a muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97196507\">",
"    <span class=\"h2\">",
"     Types of flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flaps are categorized as local, regional, and distant. As a general rule, simple local flaps are used if possible. Regional flaps or distant flaps are used if local options are not available or if a distant flap will give a better overall functional and cosmetic result. These types are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713392252\">",
"    <span class=\"h3\">",
"     Local flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local flaps utilize tissue that abuts the defect that requires coverage. These flaps are used to cover skin defects in areas without enough tissue laxity to afford primary closure. Most local flap transfers can be performed under local or sedation anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The donor site for a local flap ideally should have enough laxity to allow primary repair in addition to providing tissue to the recipient site for coverage of the defect. If primary repair of the donor site cannot be accomplished, a skin graft can be used for closure (eg, cervicofacial flap). Local flaps are commonly used in the head and neck for closure after removal of small cutaneous carcinomas. Most local flaps are random pattern flaps with no specific named vascular supply. Examples of local flaps include rhomboid flaps (",
"      <a class=\"graphic graphic_figure graphicRef77521 \" href=\"UTD.htm?1/8/1152\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56528 \" href=\"UTD.htm?34/54/35680\">",
"       figure 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50464 \" href=\"UTD.htm?42/55/43893\">",
"       figure 8",
"      </a>",
"      ), V-Y flaps (",
"      <a class=\"graphic graphic_figure graphicRef65751 \" href=\"UTD.htm?14/3/14399\">",
"       figure 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef63328 \" href=\"UTD.htm?38/8/39055\">",
"       figure 9",
"      </a>",
"      ), bilobed flaps, and Z-plasty (",
"      <a class=\"graphic graphic_figure graphicRef61176 \" href=\"UTD.htm?4/14/4335\">",
"       figure 10",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=see_link\">",
"       \"Z-plasty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The length to width ratio of a local flap is very important, and should be approximately 1:1 in most cases to ensure adequate vascular supply to the flap. This ratio is somewhat variable depending on the underlying vascularity. For example, flaps in highly vascular areas such as the face can be longer with a narrower base, while a poorly vascularized area such as the lower extremity requires that flap length be equal to flap width.",
"     </li>",
"     <li>",
"      Closure of the donor site for a local flap is usually done in two layers: a layer of absorbable deep dermal fine sutures followed by skin closure with intradermal absorbable or transcutaneous permanent suture. Monofilament sutures (either absorbable or permanent) are recommended for their decreased reactivity. Permanent sutures cause less inflammation than absorbable sutures as long as they are removed early. If the sutures are tied too tightly or left in too long, suture marks will be visible, decreasing the aesthetic result. When utilized on the face, suture should be removed in three to seven days.",
"     </li>",
"     <li>",
"      Local flaps remain erythematous and edematous for many weeks, not taking their final form for three to six months, thus any revisional procedures should be delayed until flap maturity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713392259\">",
"    <span class=\"h3\">",
"     Regional flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional flaps utilize tissue in the vicinity of the defect without actually abutting the defect. An example of a regional flap is the forehead flap for nasal tip reconstruction, which is based on the supraorbital and supratrochlear vessels, and includes the glabellar and frontalis musculature.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regional flaps use skin similar in quality and color to the recipient site, thus they are favored in the head and neck when compared with distant flaps or even skin grafts. In the face, utilizing \"like tissue\" is very important for the long-term aesthetic result.",
"     </li>",
"     <li>",
"      Regional flap design requires identification of the axial vessel upon which the tissue transfer will be based, including the arc of rotation of a flap based upon that vessel. In most cases, the vessel can be identified with a handheld Doppler, and the skin island required is usually centered over the vessel.",
"     </li>",
"     <li>",
"      Most regional flaps are musculocutaneous. Thus, the donor site morbidity of muscle harvest must be considered (see",
"      <a class=\"local\" href=\"#H601427425\">",
"       'Flap composition'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713392273\">",
"    <span class=\"h3\">",
"     Distant flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distant flaps utilize tissue far from the defect and can be transferred over a large distance as pedicled or free flaps. Numerous distant flaps have been described, including muscle flaps, musculocutaneous flaps, prelaminated and prefabricated, cutaneous, fasciocutaneous and osteocutaneous flaps. All of these flaps are transferred with the same principles:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adequate tissue must be harvested to accomplish the goal at the recipient site",
"     </li>",
"     <li>",
"      The tissue must be adequately vascularized",
"     </li>",
"     <li>",
"      The donor site morbidity should be minimized",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259477654\">",
"    <span class=\"h4\">",
"     Pedicled flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pedicled flaps, the vascular supply remains connected anatomically throughout flap transfer. Examples of a distant pedicled flap include a greater omentum flap to the head and neck area and a transverse rectus abdominis muscle (TRAM) flap (",
"    <a class=\"graphic graphic_figure graphicRef54291 \" href=\"UTD.htm?21/25/21909\">",
"     figure 11",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link&amp;anchor=H21#H21\">",
"     \"Breast reconstruction in women with breast cancer\", section on 'Pedicled TRAM flap'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601427683\">",
"    <span class=\"h4\">",
"     Free flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;For free flaps, the vascular supply is disconnected from its axial blood supply during the transfer and reconnected microsurgically to a new artery and vein at or near the recipient site. An example of a microsurgical free distant flap is a deep inferior epigastric perforator (DIEP) flap.",
"   </p>",
"   <p>",
"    Perforator flaps contain a transmuscular vascular &ldquo;leash&rdquo; or pedicle that leads to the overlying fascia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin only [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/16\">",
"     16",
"    </a>",
"    ]. The vessels are dissected out of the muscle through which they perforate, and the muscle is left behind, relatively undamaged. Thus, perforator flaps cause less morbidity at the donor site but are more technically demanding and more time consuming than pedicled flaps [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These flaps have gained favor as a way to decrease the morbidity associated with musculocutaneous flaps. As an example, the use of free tissue transfer has become commonplace in breast reconstruction, with the use of perforator flaps, such as the deep inferior epigastric perforator (DIEP) flap, often used as an alternative to the pedicled TRAM flap (",
"    <a class=\"graphic graphic_figure graphicRef66615 \" href=\"UTD.htm?14/44/15045\">",
"     figure 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link&amp;anchor=H33#H33\">",
"     \"Breast reconstruction in women with breast cancer\", section on 'Perforator flaps'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601427690\">",
"    <span class=\"h4\">",
"     Prelaminated and prefabricated flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prelaminated and prefabricated \"designer\" flaps are limited to unusual circumstances when more common anatomic flaps are inadequate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prelaminated flaps are used to replace a multiple layer structure such as the nose. An example of a prelaminated flap is the radial forearm fasciocutaneous flap [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/21\">",
"       21",
"      </a>",
"      ]. The flap is partially raised, and cartilage from the ear and a skin graft are placed on the deep surface of the flap. These will become vascularized, and then the entire construct is transferred to the recipient site as a free microvascular transfer three to six weeks later. Using this delay phenomenon, tissue transfers can be engineered, enabling the surgeon to transfer tissue with layers not normally seen in the donor site [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prefabricated flaps are created by using tissue without an axial vessel and adding a vascular leash at a first stage [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/23\">",
"       23",
"      </a>",
"      ]. If a particular type or color of skin is desired for a reconstruction, an arterial-venous pedicle is transferred intact under that skin. Vascular connections will occur over a few weeks, and then the flap can be transferred as a free flap based on the transferred vascular pedicle. Neovascularization from the transferred pedicle occurs, allowing the transfer of tissue not normally in the vascular territory of the utilized pedicle. Prefabricated flaps have been used for reconstruction of large facial defects [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601427425\">",
"    <span class=\"h2\">",
"     Flap composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local, regional, and distant flaps can contain a variety of tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/25\">",
"     25",
"    </a>",
"    ]. The decision about which flap to use depends on the defect that is being repaired. For example, tissue defects that include bone can be repaired with osteocutaneous flaps, and large or deep defects can be repaired with musculocutaneous flaps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259477833\">",
"    <span class=\"h3\">",
"     Skin flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin flaps are most commonly utilized as local flaps to cover defects from surgery or trauma. An example is the use of skin flaps to cover defects on the face after Mohs surgery. These flaps are used to cover skin defects in areas without enough tissue laxity to afford primary closure. If a local flap can be advanced to cover a defect, this is a simpler and aesthetically better method of providing closure than a skin graft, which would require surgery at a second site. (See",
"    <a class=\"local\" href=\"#H713392252\">",
"     'Local flaps'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259477841\">",
"    <span class=\"h3\">",
"     Muscle flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;A muscle flap uses muscle with associated nerve and vascular pedicles for defect coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/26\">",
"     26",
"    </a>",
"    ]. The flap blood supply is carried through the muscle and includes the overlying tissue. Muscle flaps are well vascularized and if enough skin coverage is not available, a split thickness skin graft can be placed to complete wound closure. Because these flaps harvest some or all of a particular muscle, attention must be paid to the donor site deformity resulting from the muscle sacrifice. Muscle only flaps are usually utilized for coverage of large ablative or trauma induced defects or for functional purposes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An example of a muscle",
"      <strong>",
"      </strong>",
"      flap for defect coverage is the medial gastrocnemius flap, which is based on the medial sural artery and vein. The medial gastrocnemius flap can be used to cover defects from the distal thigh down to the middle third of the calf and is often used in salvage of total knee replacement or to cover compound fractures of the proximal calf.",
"     </li>",
"     <li>",
"      Examples of muscle flaps as active transfers for functional purposes include a pedicled latissimus flap for elbow flexion and a free gracilis flap for facial reanimation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259477852\">",
"    <span class=\"h3\">",
"     Musculocutaneous flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;A musculocutaneous flap includes the muscle and overlying skin and subcutaneous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/26\">",
"     26",
"    </a>",
"    ]. Musculocutaneous flaps are used for large or deep defects, such as for breast reconstruction or deep perineal defects. An example of a musculocutaneous flap is the transverse rectus abdominis musculocutaneous (TRAM) flap for breast reconstruction (",
"    <a class=\"graphic graphic_figure graphicRef54291 \" href=\"UTD.htm?21/25/21909\">",
"     figure 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/27\">",
"     27",
"    </a>",
"    ]. A TRAM flap includes the transverse skin island from just above the umbilicus to the suprapubic region, the transverse rectus abdominis muscle, and the blood supply from the superior epigastric artery and vein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link&amp;anchor=H21#H21\">",
"     \"Breast reconstruction in women with breast cancer\", section on 'Pedicled TRAM flap'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259477870\">",
"    <span class=\"h3\">",
"     Fasciocutaneous flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasciocutaneous flaps are based on vessels arising in fascial planes in between muscles and do not intrinsically include any muscle in the design. A fasciocutaneous flap includes skin, subcutaneous tissue, and the underlying fascia. These flaps are less bulky than musculocutaneous flaps and are used to cover large superficial defects when skin alone would not provide adequate coverage. An example of a fasciocutaneous flap is an anterolateral thigh flap used for coverage of a perineogenital skin defect [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259477881\">",
"    <span class=\"h3\">",
"     Osteocutaneous flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;An osteocutaneous flap contains a bony component and is used to replace missing bone in the head and neck or long bones of the extremities. An example of an osteocutaneous flap is a fibular free flap [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713392308\">",
"    <span class=\"h2\">",
"     Flap complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flap complications include vascular compromise, hematoma, seroma, surgical site infection, and complications specific to the donor site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259477919\">",
"    <span class=\"h3\">",
"     Vascular compromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular compromise is the most common cause of flap failure. Poor flap design and failure to follow the angiosome concept of tissue blood supply can lead to partial flap loss if the flap includes too much tissue and extends beyond the anatomic boundary of the flap's blood supply. Vascular compromise can also occur due to torsion on the vascular pedicle during transfer of the flap to the recipient site. In free flaps, vascular compromise is usually due to thrombosis of either the artery or vein included in the microanastomosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pedicled flaps",
"      </strong>",
"      &ndash; Early identification of vascular compromise in pedicled grafts with color change and diminished capillary refill requires return to the operating room to check for torsion and re-inset of the flap. In some cases the flap must be temporarily returned to the donor site to allow for vascular recovery.",
"     </li>",
"     <li>",
"      <strong>",
"       Free flaps",
"      </strong>",
"      &ndash; For free flaps, the blood supply is monitored first and foremost by clinical observation of the color, temperature, capillary refill, bleeding, edema, and appearance of the flap. A simple Doppler unit is often used to evaluate both arterial and venous signals in the flap and can help improve flap salvage rates [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/30-33\">",
"       30-33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The addition of tissue oximetry can detect vascular compromise before it is clinically apparent. In a series of 614 consecutive microsurgical flaps, 380 patients were monitored with clinical inspection and Doppler ultrasound alone, 234 patients were also monitored with tissue oximetry [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12521/abstract/32\">",
"       32",
"      </a>",
"      ]. Tissue oximetry did not change the rate of re-exploration but decreased the rate of flap loss from 2.9 to 0.4 percent. If available, both Doppler ultrasound and continuous tissue oximetry should be used to monitor free flaps for vascular compromise for the first three days after surgery. Doppler ultrasound monitoring is generally performed every 15 minutes for the first hour, every 30 minutes for the second hour, every hour for the next 10 hours and then with routine vital signs every four hours. Vascular compromise of free flaps necessitates prompt return to the operating room for evaluation of the cause and potential revision of the microanastomosis and flap salvage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For total flap necrosis, the flap must be removed. For partial flap loss, the necrotic tissue requires debridement and local wound care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H55268712#H55268712\">",
"     \"Basic principles of wound management\", section on 'Wound debridement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851422551\">",
"    <span class=\"h3\">",
"     Other flap complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications of flaps include hematoma and seroma and surgical site infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications specific to the donor site can also occur. As an example, abdominal wall weakness or even frank herniation can occur after harvest of the rectus abdominus muscle for a TRAM flap. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200202797\">",
"    <span class=\"h1\">",
"     GRAFTS VERSUS FLAPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A skin graft does not have a blood supply and is dependent on vascularization from the recipient site. In contrast to a skin graft, a flap carries its own blood supply and is therefore not dependent on the recipient bed to revascularize the tissue. Thus, the decision about using a graft versus a flap is dependent on the condition and requirement of the recipient bed. A well vascularized bed can accept a graft while a devascularized bed (eg, cartilage or bone) requires flap coverage. Flaps also have more versatility and can be used to fill large defects or recreate structures such as the breast and provide better coverage over joints. In addition, size, location and aesthetics often dictate the choice between using a graft or a flap for closure. As an example, closure of nasal skin defects will have a better aesthetic outcome with a local flap of similar texture and color than if a skin graft is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1933287\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The routine use of grafts and flaps has dramatically broadened the ability of the surgeon to perform reconstructive surgery and improve outcomes and quality of life for trauma patients, burn patients, and cancer patients. (See",
"      <a class=\"local\" href=\"#H713392042\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A skin graft is defined as a transfer of skin from the donor site to the recipient site without the benefit of any blood supply. (See",
"      <a class=\"local\" href=\"#H713392049\">",
"       'Skin grafts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Split thickness skin grafts (STSG) transfer a portion of the donor site skin layer including the epidermis and some of the underlying dermis. Full thickness skin grafts harvest the entire layer of skin as the graft. (See",
"      <a class=\"local\" href=\"#H301311054\">",
"       'Types of skin grafts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proper preparation of the recipient site is crucial for both split thickness and full thickness skin grafts. Prior to grafting any wound bed, the surgeon must be sure that the bed is ready to accept the graft. The wound must be free of all necrotic or ischemic tissue. Infection should be treated and local cellulitis, significant edema, or purulent drainage should be resolved before grafting is attempted. (See",
"      <a class=\"local\" href=\"#H192764531\">",
"       'Recipient site preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chief cause of skin graft failure is graft movement, which interferes with neovascularization and encourages fluid collection under the graft, which can lead to infection and poor revascularization. (See",
"      <a class=\"local\" href=\"#H632143779\">",
"       'Graft failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A flap is defined by a transfer of skin and underlying tissue from one part of the body to another along with a blood supply. Thus, unlike grafts, flaps are not dependent on the recipient bed to vascularize the tissue that is transferred. (See",
"      <a class=\"local\" href=\"#H713392070\">",
"       'Flaps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A flap is the best approach to wound repair when primary repair is unobtainable, the wound bed is not amenable to grafting, or the aesthetics are unfavorable for grafting. (See",
"      <a class=\"local\" href=\"#H1933995\">",
"       'Indications for flap coverage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flap selection begins with an analysis of the defect location, vascularity of the defect bed, comorbidities, cosmetic significance, and functional significance. As a general rule, simpler local and regional flaps are used if possible. More complicated flaps, such as distant pedicled or free flaps, are used if simpler options are not available or if a distant flap will give a better overall functional and cosmetic result. (See",
"      <a class=\"local\" href=\"#H713392245\">",
"       'Flap choice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular compromise is the most common cause of flap failure. When partial flap loss occurs, the necrotic tissue requires debridement. (See",
"      <a class=\"local\" href=\"#H713392308\">",
"       'Flap complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/1\">",
"      Ratner D. Skin grafting. Semin Cutan Med Surg 2003; 22:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/2\">",
"      Ogawa R, Hyakusoku H, Ono S. Useful tips for successful skin grafting. J Nippon Med Sch 2007; 74:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/3\">",
"      Harrison CA, MacNeil S. The mechanism of skin graft contraction: an update on current research and potential future therapies. Burns 2008; 34:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/4\">",
"      Dirschl DR, Wilson FC. Topical antibiotic irrigation in the prophylaxis of operative wound infections in orthopedic surgery. Orthop Clin North Am 1991; 22:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/5\">",
"      Ratner D. Skin grafting. From here to there. Dermatol Clin 1998; 16:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/6\">",
"      Housewright CD, Lenis A, Butler DF. Oscillating electric dermatome use for harvesting split-thickness skin grafts. Dermatol Surg 2010; 36:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/7\">",
"      Currie LJ, Sharpe JR, Martin R. The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. Plast Reconstr Surg 2001; 108:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/8\">",
"      Sterling JB, Skouge JW. Surgical glue to secure small split-thickness skin grafts: a cost-effective and time-saving technique. Dermatol Surg 2008; 34:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/9\">",
"      Chen TM, Tsai JC, Burnouf T. A novel technique combining platelet gel, skin graft, and fibrin glue for healing recalcitrant lower extremity ulcers. Dermatol Surg 2010; 36:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/10\">",
"      Scherer LA, Shiver S, Chang M, et al. The vacuum assisted closure device: a method of securing skin grafts and improving graft survival. Arch Surg 2002; 137:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/11\">",
"      Pribaz JJ, Chester CH, Barrall DT. The extended V-Y flap. Plast Reconstr Surg 1992; 90:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/12\">",
"      Guo L, Pribaz JR, Pribaz JJ. Nasal reconstruction with local flaps: a simple algorithm for management of small defects. Plast Reconstr Surg 2008; 122:130e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/13\">",
"      Taylor GI, Palmer JH. The vascular territories (angiosomes) of the body: experimental study and clinical applications. Br J Plast Surg 1987; 40:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/14\">",
"      Taylor GI, Corlett RJ, Dhar SC, Ashton MW. The anatomical (angiosome) and clinical territories of cutaneous perforating arteries: development of the concept and designing safe flaps. Plast Reconstr Surg 2011; 127:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/15\">",
"      Taylor GI, Pan WR. Angiosomes of the leg: anatomic study and clinical implications. Plast Reconstr Surg 1998; 102:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/16\">",
"      Sinna R, Boloorchi A, Mahajan AL, et al. What should define a \"perforator flap\"? Plast Reconstr Surg 2010; 126:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/17\">",
"      Blondeel PN, Van Landuyt KH, Monstrey SJ, et al. The \"Gent\" consensus on perforator flap terminology: preliminary definitions. Plast Reconstr Surg 2003; 112:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/18\">",
"      Massey MF, Spiegel AJ, Levine JL, et al. Perforator flaps: recent experience, current trends, and future directions based on 3974 microsurgical breast reconstructions. Plast Reconstr Surg 2009; 124:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/19\">",
"      Allen RJ, Treece P. Deep inferior epigastric perforator flap for breast reconstruction. Ann Plast Surg 1994; 32:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/20\">",
"      Gill PS, Hunt JP, Guerra AB, et al. A 10-year retrospective review of 758 DIEP flaps for breast reconstruction. Plast Reconstr Surg 2004; 113:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/21\">",
"      Chiang YC. Combined tissue expansion and prelamination of forearm flap in major ear reconstruction. Plast Reconstr Surg 2006; 117:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/22\">",
"      Pribaz JJ, Fine NA. Prefabricated and prelaminated flaps for head and neck reconstruction. Clin Plast Surg 2001; 28:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/23\">",
"      Yao ST. Vascular implantation into skin flap: experimental study and clinical application: a preliminary report. Plast Reconstr Surg 1981; 68:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/24\">",
"      Liu X, Li S, Li Y. Prefabricated cervical flap for facial reconstruction. Plast Reconstr Surg 2008; 121:342e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/25\">",
"      Ciresi KF, Mathes SJ. The classification of flaps. Orthop Clin North Am 1993; 24:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/26\">",
"      Mathes SJ, Alpert BS. Advances in muscle and musculocutaneous flaps. Clin Plast Surg 1980; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/27\">",
"      Hartrampf CR, Scheflan M, Black PW. Breast reconstruction with a transverse abdominal island flap. Plast Reconstr Surg 1982; 69:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/28\">",
"      Luo S, Raffoul W, Piaget F, Egloff DV. Anterolateral thigh fasciocutaneous flap in the difficult perineogenital reconstruction. Plast Reconstr Surg 2000; 105:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/29\">",
"      Ghaheri BA, Kim JH, Wax MK. Second osteocutaneous fibular free flaps for head and neck defects. Laryngoscope 2005; 115:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/30\">",
"      Salgado CJ, Moran SL, Mardini S. Flap monitoring and patient management. Plast Reconstr Surg 2009; 124:e295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/31\">",
"      Paydar KZ, Hansen SL, Chang DS, et al. Implantable venous Doppler monitoring in head and neck free flap reconstruction increases the salvage rate. Plast Reconstr Surg 2010; 125:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/32\">",
"      Lin SJ, Nguyen MD, Chen C, et al. Tissue oximetry monitoring in microsurgical breast reconstruction decreases flap loss and improves rate of flap salvage. Plast Reconstr Surg 2011; 127:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12521/abstract/33\">",
"      Rozen WM, Chubb D, Whitaker IS, Acosta R. The efficacy of postoperative monitoring: a single surgeon comparison of clinical monitoring and the implantable Doppler probe in 547 consecutive free flaps. Microsurgery 2010; 30:105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15118 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.211.0.116-73B16972F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12521=[""].join("\n");
var outline_f12_14_12521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1933287\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H713392042\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H713392049\">",
"      SKIN GRAFTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H632143838\">",
"      Indications for skin grafting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H301311054\">",
"      Types of skin grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H713392056\">",
"      - Split thickness skin grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H713392063\">",
"      - Full thickness skin grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H301311091\">",
"      Choice of split versus full thickness grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H301310968\">",
"      Surgical technique for skin grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192764524\">",
"      - Donor site selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192764531\">",
"      - Recipient site preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H516241821\">",
"      - STSG technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H451034789\">",
"      - FTSG technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H632143769\">",
"      Graft maturation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H632143779\">",
"      Graft failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H713392070\">",
"      FLAPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1933995\">",
"      Indications for flap coverage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H301310853\">",
"      Blood supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H713392231\">",
"      Site preparation for flaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H713392245\">",
"      Flap choice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97196507\">",
"      Types of flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H713392252\">",
"      - Local flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H713392259\">",
"      - Regional flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H713392273\">",
"      - Distant flaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H259477654\">",
"      Pedicled flaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H601427683\">",
"      Free flaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H601427690\">",
"      Prelaminated and prefabricated flaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H601427425\">",
"      Flap composition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259477833\">",
"      - Skin flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259477841\">",
"      - Muscle flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259477852\">",
"      - Musculocutaneous flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259477870\">",
"      - Fasciocutaneous flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259477881\">",
"      - Osteocutaneous flaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H713392308\">",
"      Flap complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259477919\">",
"      - Vascular compromise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H851422551\">",
"      - Other flap complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200202797\">",
"      GRAFTS VERSUS FLAPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1933287\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15118\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15118|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/17/274\" title=\"figure 1\">",
"      Placement of meshed skin graft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/21/23889\" title=\"figure 2\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/21/9558\" title=\"figure 3\">",
"      Whole body Langers lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/4/32837\" title=\"figure 4\">",
"      Langers lines of the face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/8/1152\" title=\"figure 5\">",
"      Rhomboid flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/54/35680\" title=\"figure 6\">",
"      Triple rhomboid hexagonal flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/3/14399\" title=\"figure 7\">",
"      V Y advancement flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/55/43893\" title=\"figure 8\">",
"      Rhomboid flap for closure of a vulvar defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/8/39055\" title=\"figure 9\">",
"      V-Y advancement for anal fissures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/14/4335\" title=\"figure 10\">",
"      Classic z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/25/21909\" title=\"figure 11\">",
"      Pedicled TRAM flap reconstruction after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/44/15045\" title=\"figure 12\">",
"      DIEP flap breast reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15118|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/63/34802\" title=\"picture 1\">",
"      Harvested STSG meshed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/0/39937\" title=\"picture 2\">",
"      Split thickness skin graft and skin mesher",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/6/7265\" title=\"picture 3\">",
"      Split thickness skin graft meshing process",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/59/35765\" title=\"picture 4\">",
"      Meshed skin graft",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15118|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/57/10140\" title=\"table 1\">",
"      Oral antibiotics for infections due to MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/12/23756\" title=\"table 2\">",
"      Empiric antibiotics cellulitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=related_link\">",
"      Mandibular and palatal reconstruction in patients with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=related_link\">",
"      Principles of burn reconstruction: Overview of surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37064?source=related_link\">",
"      Treatment of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5177?source=related_link\">",
"      Wound healing and risk factors for non-healing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=related_link\">",
"      Z-plasty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_14_12522="Immunotherapy of renal cell carcinoma";
var content_f12_14_12522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunotherapy of renal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/14/12522/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12522/contributors\">",
"     Daniel George, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12522/contributors\">",
"     Eric Jonasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/14/12522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12522/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/14/12522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/14/12522/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/14/12522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection of localized renal cell cancer (RCC) can be curative for localized disease, but many patients eventually recur. In addition, many RCCs are clinically silent for much of their course, and the initial diagnosis is often delayed until disease is either locally advanced and unresectable or metastatic. The prognosis for patients with advanced or metastatic RCC is generally poor, although survival estimates from different series are influenced by patient selection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most patients with advanced RCC, anti-angiogenic therapy or the administration of a molecularly targeted agent are the preferred treatments. However, for select patients, immunotherapy can result in durable long-term remissions. Therefore, immunotherapy continues to be a treatment option for some patients with advanced RCC.",
"   </p>",
"   <p>",
"    This topic will review immunotherapy of advanced renal cell carcinoma, including the use of IL-2, IFNa, and experimental approaches. An overview of the treatment approach to RCC, prognostic factors in RCC, and the use of anti-angiogenic and molecularly targeted therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21528?source=see_link\">",
"     \"Overview of the treatment of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350646872\">",
"    <span class=\"h1\">",
"     RATIONALE FOR IMMUNOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of primary RCCs can evoke an immune response that occasionally results in spontaneous and dramatic remissions in metastases, particularly in the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Various immunotherapeutic strategies have been used to augment antitumor immunity, including the administration of cytokines, specific antitumor immunotherapy, adoptive immunotherapy, the induction of a graft-versus-tumor response via allogeneic hematopoietic stem cell transplantation, and nonspecific stimulators of the immune system.",
"   </p>",
"   <p>",
"    Clinically useful antitumor activity has been seen with the cytokines interleukin-2 (IL-2) and interferon alfa (IFNa); among the immunotherapies, high-dose IL-2 was established as the preferred treatment for patients with advanced RCC and good organ function in the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/3\">",
"     3",
"    </a>",
"    ]. Although the mechanisms of action of IL-2 and IFNa are poorly understood, the induction of antitumor immunity in murine models involved direct killing of tumor cells by activated T cells and natural killer (NK) cells. In addition, IFNa may have antiangiogenic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350646879\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For previously untreated patients with RCC, both immunotherapy and molecularly targeted agents are reasonable options.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a good Karnofsky performance status (KPS) (&ge;80 percent) (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 1",
"      </a>",
"      ) and intact organ function, we suggest immunotherapy rather than targeted therapy. Of the available immunotherapeutic treatments, we prefer IL-2 rather than interferon alfa or other immunotherapeutic approaches. IL-2 results in a durable long-term remission in approximately 10 percent of patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interleukin-2'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients who are not candidates for or who decline IL-2 (including those patients without access to IL-2 therapy), we recommend molecularly targeted therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERLEUKIN-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial use of interleukin-2 (IL-2) in RCC combined high-dose bolus therapy with the infusion of lymphokine-activated killer (LAK) cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/4\">",
"     4",
"    </a>",
"    ]. Dramatic and durable responses were reported in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Subsequent studies found that high-dose bolus IL-2 alone was as active as the combination of IL-2 and LAK [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     High-dose IV bolus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of high-dose bolus IL-2 is based upon its ability to induce durable, high-quality remissions in a minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In seven phase II studies, recombinant IL-2 (600,000 to 720,000 international units per kg) was administered as a 15 minute intravenous (IV) infusion every eight hours over five consecutive days (up to 14 consecutive doses). A course of therapy consisted of such two cycles, beginning on days 1 and 15. &nbsp;Responding patients and those with stable disease were retreated approximately every 12 weeks for a maximum of three courses.",
"   </p>",
"   <p>",
"    High-dose bolus IL-2 treatment was associated with severe toxicity (",
"    <a class=\"graphic graphic_table graphicRef67823 graphicRef80320 \" href=\"UTD.htm?0/1/20\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, this protocol was restricted to carefully selected patients with excellent organ function who could be treated in a setting capable of providing blood pressure support.",
"   </p>",
"   <p>",
"    The following results were reported for 259 patients treated with this high-dose bolus IL-2 schedule at the National Cancer Institute between 1986 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Objective responses were observed in 53 patients (20 percent); these included 30 partial responses (PRs) and 23 complete responses (CRs). Maximal response often took a prolonged period to develop, and surgery rendered six patients disease free after an initial PR to IL-2 treatment.",
"     </li>",
"     <li>",
"      Among the patients who achieved a CR, 19 of 23 (83 percent) remained free of recurrence at last follow-up. The four patients who relapsed all did so within the first four years after treatment. In contrast, all of the patients who had a PR eventually recurred, predominantly within the first three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were seen in another series of 212 patients treated with high-dose IL-2, in which an overall response rate of 20 percent was observed. This included 16 patients (8 percent) with complete responses and a median survival of over 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, it appears that many responding patients who were progression-free for more than three years or who underwent posttreatment surgical resection were",
"    <strong>",
"     cured",
"    </strong>",
"    of metastatic RCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alternative schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative schedules have been evaluated to increase the antitumor efficacy of IL-2 or decrease its toxicity while maintaining activity. These approaches have included using intermediate or low doses of IL-2 by continuous infusion or subcutaneously (SC) or by combining IL-2 with IFNa.",
"   </p>",
"   <p>",
"    Results from several large randomized trials have been reported.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NCI Trial &mdash; The National Cancer Institute (NCI) conducted a large-scale randomized phase III trial comparing the standard high-dose bolus IL-2 schedule with a low-dose intravenous bolus regimen using 10 percent of the standard dose and with an outpatient regimen using SC IL-2 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/13\">",
"       13",
"      </a>",
"      ]. The main results were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among the 306 patients randomly assigned to high-dose or low-dose intravenous IL-2, the response rate was significantly higher with high-dose therapy (21 versus 13 percent with the low-dose schedule), with a trend toward more durable responses. Although toxicities were also significantly greater in the high-dose group (particularly hypotension), there were no deaths attributable to IL-2 in either arm.",
"     </li>",
"     <li>",
"      Among the 190 patients assigned to high-dose IV IL-2 or SC IL-2, there was a significantly higher response rate with high-dose IV IL-2 (21 versus 10 percent with the SC schedule).",
"     </li>",
"     <li>",
"      There were no differences in overall survival among the three groups. However, additional follow-up is necessary, since the main benefit of IL-2 administration is not the initial response rate but the induction of durable, complete responses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytokine Working Group Trial &mdash; The Cytokine Working Group (CWG) evaluated outpatient administration of IL-2 plus IFN (both administered as a subcutaneous injection) in a phase III trial of 193 patients, using high-dose bolus IL-2 as the comparison regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/14\">",
"       14",
"      </a>",
"      ]. The main results were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significantly higher objective response rate was seen with high-dose bolus IL-2 compared to the outpatient schedule (23 versus 10 percent).",
"     </li>",
"     <li>",
"      Eight patients treated with high-dose IL-2 achieved a CR and 10 were progression-free at three years. Only three patients had a CR with the outpatient schedule, and none were durable.",
"     </li>",
"     <li>",
"      A trend toward improved survival was noted in the group treated with high-dose IL-2 (17.5 versus 13 months).",
"     </li>",
"     <li>",
"      Patients receiving high-dose IL-2 had a diminished quality of life (QOL) on some symptoms scales early in therapy, but experienced overall improved functional and symptomatic QOL during the course of treatment, compared to those receiving the outpatient combination [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      French multicenter trial &mdash; A multicenter French trial randomly assigned 425 patients to intermediate-dose IL-2 administered by continuous IV infusion, subcutaneous IFNa, or a combination of these agents by the same routes of administration [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/16\">",
"       16",
"      </a>",
"      ]. Although the response rate was significantly higher for combined therapy than for either single agent (18.6 versus 6.5 and 7.5 percent, IL-2 and IFNa, respectively), the differences in survival at one year were not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     IL-2 plus cellular therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial trials comparing high-dose IL-2 plus lymphokine-activated killer (LAK) cells to IL-2 alone concluded that the efficacy of high-dose bolus IL-2 was equivalent to that of",
"    <span class=\"nowrap\">",
"     IL-2/LAK",
"    </span>",
"    cells. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Interleukin-2'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The combination of low-dose, continuous infusion IL-2 and CD8-positive tumor infiltrating lymphocytes (TILs) appeared to give an improved response rate in a phase II study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/17\">",
"     17",
"    </a>",
"    ]. However, in a subsequent trial, 160 patients with advanced renal cell carcinoma were randomly assigned to IL-2 alone or with an infusion of autologous CD8-positive TILs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/18\">",
"     18",
"    </a>",
"    ]. Intention to treat analysis revealed low response rates for both treatment arms and no survival difference. Unfortunately, many patients assigned to the TILs arm did not receive TILs due to technical problems. Although this study is difficult to interpret, there does",
"    <strong>",
"     not",
"    </strong>",
"    appear to be a clear benefit from the addition of TILs to low-dose IL-2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Predictors of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Responses to high-dose IL-2 are often of long duration and high quality, which must be balanced against the cost, limited access, and toxicity associated with high-dose IL-2 treatment. Thus, efforts have been made to identify clinical, histologic, and molecular characteristics that can identify the patient subsets that are most likely to benefit from this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clinical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical factors that reflect a large tumor burden or rapid disease progression are associated with less frequent responses that are of shorter duration. These factors include the presence of more than one site of metastatic disease, a progression-free interval of less than one year, and the presence of liver or mediastinal lymph node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients with all of these characteristics had &gt;70 percent chance of rapid disease progression and a median survival of six months in one series.",
"   </p>",
"   <p>",
"    Prior nephrectomy and time from nephrectomy to relapse are important predictors of improved survival in patients receiving IL-2 therapy. In one report, patients who began immunotherapy at least six months after nephrectomy had the best median survival and a 46 percent three-year survival rate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors associated with a favorable prognosis include a good performance status and the absence of bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/20\">",
"     20",
"    </a>",
"    ]. Clinical or laboratory observations after the initial treatment that correlate with a subsequent antitumor response and an improved prognosis include the development of thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/21\">",
"     21",
"    </a>",
"    ], thyroid dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/22\">",
"     22",
"    </a>",
"    ], rebound lymphocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/23\">",
"     23",
"    </a>",
"    ], low circulating levels of monocytes and granulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/24\">",
"     24",
"    </a>",
"    ], and elevation of tumor necrosis factor (TNF) and interleukin-1 (IL-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Histology and CAIX expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Responses to immunotherapy are typically observed in patients with clear cell RCCs. This was illustrated in a report in which pathology specimens were obtained from 231 patients undergoing IL-2 therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/26\">",
"     26",
"    </a>",
"    ]. The primary tumor was available for analysis in 163 cases. Responses were observed in 30 of 146 patients with clear cell carcinoma (21 percent), compared to 1 of 17 cases with nonclear cell histology (6 percent). Similarly, in the prospective, single-arm SELECT trial, 120 patients were treated with high-dose IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/27\">",
"     27",
"    </a>",
"    ]. In preliminary results presented at the 2010 American Society of Clinical Oncology (ASCO) meeting, objective responses were seen in 34 of 115 patients (30 percent) with clear cell histology but 0 of 5 with nonclear cell histology. As a consequence, many oncologists do not use IL-2 therapy in patients with nonclear cell histology.",
"   </p>",
"   <p>",
"    Among the patients with clear cell carcinomas, other histologic features may provide additional prognostic information. In a retrospective series, responses to IL-2 were associated with the presence of alveolar features in more than 50 percent of the sample, and an absence of papillary features or granular features [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/26\">",
"     26",
"    </a>",
"    ]. Similarly, high levels of carbonic anhydrase IX (CAIX) expression appear to be associated with a more favorable prognosis and potentially a greater likelihood of a response to immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Although retrospective studies suggested that these parameters might have utility in predicting responsiveness to IL-2 therapy, efforts to combine histologic features and CAIX expression to predict responsiveness to IL-2 were unsuccessful in the prospective SELECT trial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link&amp;anchor=H7#H7\">",
"     \"Prognostic factors in patients with renal cell carcinoma\", section on 'Molecular markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7375113\">",
"    <span class=\"h3\">",
"     Sarcomatoid RCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomatoid features or sarcomatoid dedifferentiation can be seen in all types of RCC specimens. The role of immunotherapy in patients with the sarcomatoid variant of RCC is unclear. One review of 31 consecutive cases of sarcomatoid RCC found that those treated with nephrectomy followed by high-dose IL-2 had a median survival of more than ten months, which was significantly longer than that of patients undergoing surgery alone or any other form of immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/30\">",
"     30",
"    </a>",
"    ]. Other series report an objective response in 25 to 33 percent of patients receiving systemic immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/31\">",
"     31",
"    </a>",
"    ]. Nonetheless, it is generally believed that durable responses to immunotherapy are unlikely in patients with tumors containing sarcomatoid features.",
"   </p>",
"   <p>",
"    Patients with tumors showing predominantly sarcomatoid features also have been reported to respond to doxorubicin-based chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], as well as molecularly targeted therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], so such approaches can be considered alternatives in this patient population, especially in patients with non-clear cell tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21528?source=see_link&amp;anchor=H1056311562#H1056311562\">",
"     \"Overview of the treatment of renal cell carcinoma\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with IL-2 is associated with severe toxicity affecting multiple organ systems. These complications include hypotension, cardiac arrhythmias, metabolic acidosis, fever, nausea and vomiting, dyspnea, edema, oliguria and renal failure, neurotoxicity, and dermatologic complications. Use of high-dose regiments requires treatment in a setting of providing blood pressure support. Guidelines are available for the clinical management of these complications (",
"    <a class=\"graphic graphic_table graphicRef67823 graphicRef80320 \" href=\"UTD.htm?0/1/20\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms underlying IL-2 toxicity are not fully understood. Several mechanisms have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IL-2 is a strong stimulator of proinflammatory cytokines (eg, IL-1, TNFa, and interferon gamma [IFNg]) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/37-39\">",
"       37-39",
"      </a>",
"      ] and of nitric oxide [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/40\">",
"       40",
"      </a>",
"      ]. These substances may mediate much of the treatment-related toxicity.",
"     </li>",
"     <li>",
"      A protein fragment of the IL-2 molecule that has tentatively been identified may be responsible for vasopermeability [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 18 patients, serum levels of angiopoietin 2 rose progressively in all cases with high-dose IL-2 therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/42\">",
"       42",
"      </a>",
"      ]. Elevated levels of serum angiopoietin 2 have previously been identified in septic patients with vascular leak syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the antitumor response is thought to be mediated via cellular immune mechanisms, raising the possibility of dissociating toxicity from antitumor efficacy by combining cytokine inhibitors with IL-2.",
"   </p>",
"   <p>",
"    Several experimental approaches have been tried in an effort to separate the toxicity of IL-2 from its antitumor activity, but these approaches have not proven useful in a clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/43-50\">",
"     43-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Relapses after response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with metastatic RCC who achieve a PR with IL-2 eventually relapse. In a series from the NCI, for example, 86 percent of 64 patients who had a PR relapsed, as opposed to less than half of the 43 who had a CR [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/51\">",
"     51",
"    </a>",
"    ]. Relapses primarily occurred in new sites in those with a CR, and in new or old sites in those with a PR. In patients with isolated recurrences, surgical metastasectomy has occasionally been successful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=see_link\">",
"     \"Role of surgery in patients with metastatic renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who relapsed after an initial response had a low rate of response (2 percent) to retreatment with IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/51\">",
"     51",
"    </a>",
"    ]. Given these low response rates, further IL-2 therapy is generally not indicated. Such patients should be considered for antiangiogenic therapy with agents like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or for participation in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INTERFERON ALFA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activity of monotherapy with IFNa in metastatic RCC has been extensively evaluated in several large, well-designed trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/16,52-55\">",
"     16,52-55",
"    </a>",
"    ]. Using a variety of preparations, doses, and schedules, the overall response rate may be as high as 15 percent; the median time to response is about four months, and most responses are partial and rarely persist beyond one year. Although no clear dose-response relationship has been shown, daily doses ranging from 5 to 10 MU appear to have the most favorable therapeutic index.",
"   </p>",
"   <p>",
"    The impact of IFNa on survival was demonstrated in a Cochrane meta-analysis that included four studies involving a total of 644 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/56\">",
"     56",
"    </a>",
"    ]. Treatment with IFNa was superior to controls (odds ratio for death at one year 0.56, 95% CI 0.40-0.77 and an overall hazard ratio for death 0.74, 95% CI 0.63-0.88). The weighted average median improvement in survival was 3.8 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     IFNa combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general availability and limited toxicity of IFNa have made it an excellent agent to combine with novel treatments and to use as the control in phase III trials. With the advent of active antiangiogenic and molecularly targeted agents, the role for IFNa in the treatment of patients with advanced RCC has diminished considerably. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     IFNa plus IL-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of IFNa plus IL-2 have been studied in patients with RCC, both with and without cytotoxic agents, based upon promising results in murine tumor models [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. IFNa upregulates the expression of HLA class I and tumor-associated antigens, thereby potentially increasing the immunogenicity of tumor cells and their susceptibility to IL-2-mediated cell lysis.",
"   </p>",
"   <p>",
"    These combinations have various schedules and routes of administration for IL-2. These variations have included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IL-2 as a high-dose IV bolus injection [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/20,59-63\">",
"       20,59-63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intermediate-dose levels of IL-2, administered as a continuous IV infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/14,16\">",
"       14,16",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Alternative schedules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IL-2 as a low-dose SC injection, often including the addition of various cytotoxic agents [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/64-71\">",
"       64-71",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Alternative schedules'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some phase II studies have reported either a higher response rate or lower toxicity than would have been expected with high-dose IL-2. However, large randomized trials with these combinations have been disappointing. These approaches have not demonstrated an improvement in overall survival compared to IFNa alone or a comparable level of durable long-term remissions compared to high-dose IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Interleukin-2'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although phase II studies suggested increased activity when IFNa was combined with chemotherapy, randomized trials have",
"    <strong>",
"     not",
"    </strong>",
"    demonstrated increased survival when combination regimens were compared to IFNa monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/73,74\">",
"     73,74",
"    </a>",
"    ] or from the addition of cis-retinoic acid to IFNa [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/67,75,76\">",
"     67,75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most promising results were seen with the combination of 5-fluorouracil and IFNa, which has produced responses in nearly one-third of patients in some trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/77-79\">",
"     77-79",
"    </a>",
"    ], including occasional patients who have progressed following IL-2 therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/80\">",
"     80",
"    </a>",
"    ]. However, randomized trials have not compared this regimen to IFNa alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome and prognostic factors were analyzed in a retrospective review of 463 patients treated at Memorial Sloan Kettering Cancer Center with advanced RCC following treatment with IFNa in six prospective clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/55\">",
"     55",
"    </a>",
"    ]. Key findings included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median survival and time to progression (TTP) were 13 and 4.7 months, respectively. The proportion of patients remaining progression-free at 6, 12, 24, and 36 months was 42, 24, 14, and 8 percent, respectively.",
"     </li>",
"     <li>",
"      Five factors independently predicted for poorer survival: KPS &lt;80 percent (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 1",
"      </a>",
"      ), serum lactic dehydrogenase (LDH) &gt;1.5 times the upper limit of normal, corrected serum calcium &gt;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      serum hemoglobin below the lower limit of normal, and an interval of less than 12 months from the initial diagnosis to use of IFNa.",
"     </li>",
"     <li>",
"      Prognosis differed significantly for those with none (good risk), one or two (intermediate risk), or three or more of the Memorial Sloan Kettering Cancer Center risk factors (poor risk) (",
"      <a class=\"graphic graphic_table graphicRef61752 \" href=\"UTD.htm?2/7/2172\">",
"       table 3",
"      </a>",
"      ). The good risk patients had better median survival (30 versus 14 and 5 months for intermediate and poor risk patients), survival at one year (83 versus 58 and 20 percent), two years (55 versus 31 and 6 percent), and three years (45 versus 17 and 2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     IFNa versus molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of agents targeting the vascular endothelial growth factor (VEGF) pathway and the mammalian target of rapamycin (mTOR) pathway has provided agents that are both more active and potentially less toxic than IFNa. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , a VEGF receptor inhibitor, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    , an mTOR inhibitor, have shown significant clinical activity with prolonged progression-free or overall survival or both compared to IFNa in randomized clinical trials. On the other hand, no benefit was seen in terms of median PFS for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    relative to IFNa in a randomized phase II trial conducted in patients with previously untreated RCC. The results of these trials are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CYTOREDUCTIVE (DEBULKING) NEPHRECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with metastatic RCC generally have a poor prognosis. However, there are case reports of regression of metastases after removal of the primary tumor (cytoreductive or debulking nephrectomy), although this is seen in 1 percent of patients or less [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/81\">",
"     81",
"    </a>",
"    ]. More importantly, two randomized trials demonstrated a survival benefit following removal of the primary tumor in carefully selected patients with metastatic RCC who subsequently underwent immunotherapy with interferon alfa [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/53,82\">",
"     53,82",
"    </a>",
"    ]. A survival benefit has not been established for cytoreductive nephrectomy in patients with non-clear cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of these trials and the criteria for patient selection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of surgery in patients with metastatic renal cell carcinoma\", section on 'Cytoreductive nephrectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OTHER IMMUNOTHERAPY APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Nonmyeloablative allogeneic hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation can induce a graft-versus-tumor effect in patients with solid tumors as well as hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. RCC appears to be uniquely sensitive to immunomodulation and thus potentially susceptible to a graft-versus-tumor effect. Nonmyeloablative preparative techniques and the use of peripheral blood lymphocytes from HLA-matched donors have given this procedure improved tolerability and more widespread applicability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary experience with nonmyeloablative allogeneic transplantation has been encouraging in some [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/87-89\">",
"     87-89",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/90\">",
"     90",
"    </a>",
"    ], reports. The potential efficacy of this approach was illustrated by a trial in which 19 patients with refractory metastatic RCC underwent nonmyeloablative allogeneic transplantation from HLA-identical or single HLA locus-mismatched sibling donors. Ten patients (53 percent) had an objective response [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/87\">",
"     87",
"    </a>",
"    ]. Tumor responses were delayed, occurring after all of the recipient's T cells were of donor origin. In 8 of the 10 responders, metastases regressed only after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    was withdrawn.",
"   </p>",
"   <p>",
"    Factors associated with a treatment response included conversion to 100 percent donor T cells, clear cell histology, and development of graft-versus-host disease (GVHD). The probability of disease response after an episode of grade 2 to 4 GVHD was 90 percent. An update of this series confirmed these early results in 47 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/91\">",
"     91",
"    </a>",
"    ]. Four of 22 responses were complete (three sustained), and 18 were partial; pulmonary metastases were most likely to respond.",
"   </p>",
"   <p>",
"    In patients with relapsed hematologic malignancies following allogeneic hematopoietic cell transplantation, reinfusion of unmanipulated donor mononuclear cells can result in significant clinical responses, although the mechanism underlying benefit is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\", section on 'Donor lymphocyte infusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This approach has been applied to patients with RCC. In one report, three cases of disease regression were noted among nine patients who received irradiated, partially HLA-matched allogeneic blood mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/92\">",
"     92",
"    </a>",
"    ]. These preliminary data require confirmation in larger studies.",
"   </p>",
"   <p>",
"    Although early results with allogeneic hematopoietic cell transplantation are promising, nonprotocol use of this approach for patients with advanced RCC is",
"    <strong>",
"     not",
"    </strong>",
"    warranted until further experience is gained. At present, allogeneic stem cell transplantation and donor lymphocyte infusion should only be performed in the context of a clinical trial. Conditioning regimens must be made less toxic, and posttransplant immunosuppression refined in order to decrease graft failure and GVHD, and to allow the use of unrelated donor bone marrow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Dendritic cell vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of vaccination with hybrid cells consisting of fused autologous tumor and allogeneic dendritic cells was assessed in 17 patients with metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/93\">",
"     93",
"    </a>",
"    ]. At a mean follow-up of 13 months, complete tumor regression was observed in four patients and partial regression in two patients. In another phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    clinical study using a similarly vaccine, one partial response and three patients with stable disease were observed among nine patients evaluable for response [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were noted using autologous dendritic cells pulsed with lysate made from cultured",
"    <span class=\"nowrap\">",
"     autologous/allogeneic",
"    </span>",
"    tumor cells, with peptides that bind to HLA-A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional investigations with dendritic cell vaccines are ongoing, particularly in conjunction with cytokines such as IL-12 or GM-CSF, which are used as vaccine adjuvants to improve the immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Interferon gamma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent interferon gamma (IFNg) therapy has minimal or no activity in patients with RCC. Although preliminary studies suggested benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/98,99\">",
"     98,99",
"    </a>",
"    ], this was not confirmed in a phase III trial from the Canadian Urologic Group in which 197 patients were randomly assigned to IFNg or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/2\">",
"     2",
"    </a>",
"    ]. There were no significant differences in overall response rates (4.4 versus 6.6 percent for active and placebo groups, respectively), TTP (1.9 months in both groups), or survival (12.2 versus 15.7 months), and only one patient in the IFNg group had a durable CR. In other studies, the combination of IFNa and IFNg did not improve upon the results of IFNa alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Other interleukins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other interleukins that have been evaluated include IL-4 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/102\">",
"     102",
"    </a>",
"    ], IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/103\">",
"     103",
"    </a>",
"    ], and IL-12 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. The encouraging results seen in animal studies with the combination of IL-12 plus IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/106\">",
"     106",
"    </a>",
"    ] have not been confirmed in human clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     ADJUVANT IMMUNOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to support a benefit for adjuvant immunotherapy in high-risk patients who have undergone potentially curative surgery. At least seven randomized multicenter trials have",
"    <strong>",
"     failed",
"    </strong>",
"    to demonstrate a survival benefit from this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/108-114\">",
"     108-114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial conducted by the Eastern Cooperative Oncology Group (ECOG) in which 283 patients with stage T3b, T3c, T4",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      N1 to N3 (",
"      <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"       table 4",
"      </a>",
"      ) disease were randomly assigned to IFNa therapy or observation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/108\">",
"       108",
"      </a>",
"      ]. At a median follow-up of 10 years, adjuvant IFNa was not associated with a significant improvement in either disease-free or overall survival.",
"     </li>",
"     <li>",
"      An EORTC trial that randomly assigned 270 patients with Robson stage II or III RCC to IFNa-2a versus no therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An Italian trial in which 310 patients were randomly assigned immunotherapy with low-dose IL-2 plus IFNa versus no therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An Italian trial in which 247 patients with Robson stage II or III RCC randomly assigned to IFNa-2b or observation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A German trial that randomly assigned 203 patients with resected stage III disease or a completely resected local recurrence or solitary metastasis to IFNa plus 5-FU, eight weeks of low-dose SC IL-2, or no treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Cytokine Working Group trial in which 69 high-risk patients were randomly assigned to a single cycle of high-dose IL-2 or observation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An EORTC trial that randomly assigned 309 patients to treatment with IL-2, IFNa, plus 5-fluorouracil or to observation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Autologous tumor vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous tumor cell vaccines have been used as an adjuvant in high-risk patients. At least two different vaccines have been assessed in randomized phase III clinical trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A German trial randomly assigned 558 patients with resected pT2-3b, pN0-3, M0 RCC (",
"      <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"       table 4",
"      </a>",
"      ) to six monthly injections of autologous tumor cell vaccine or no adjuvant therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/115\">",
"       115",
"      </a>",
"      ]. At a minimum 4.5 year follow-up, vaccine therapy was associated with significantly better five-year progression free survival (77 versus 68 percent). In subgroup analysis, benefit was seen in patients with T3 tumors (five-year PFS 68 versus 50 percent), but not T2 tumors (five-year PFS 81 versus 75 percent). Methodologic issues complicate interpretation of these results. Of the 553 patients, 174 were not treated after randomization (99 of the vaccine group and 75 controls) due to ineligibility or inability to produce vaccine.",
"     </li>",
"     <li>",
"      An alternative approach has used peptides from individual tumors in conjunction with heat shock proteins to generate a vaccine. This was used as an adjuvant in a randomized phase III trial that included 728 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/14/12522/abstract/116\">",
"       116",
"      </a>",
"      ]. After a median follow-up of 1.9 years, there was no significant difference in the recurrence rate (38 versus 40 percent, HR 0.92).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=see_link\">",
"       \"Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a good Karnofsky performance status (KPS) (&ge;80 percent) (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 1",
"      </a>",
"      ) and intact organ function, we suggest high-dose interleukin-2 (IL-2) therapy rather than targeted therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interleukin-2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who decline or are not candidates for IL-2 (including those patients without access to IL-2 therapy), we recommend molecularly targeted therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      The patients most likely to benefit from IL-2 treatment are those with clear cell carcinomas. Among patients with clear cell RCC, tumors with alveolar features but without papillary or greater than 50 percent granular features are more likely to respond. Expression of CAIX in more than 85 percent of cells in a biopsy specimen is also a potential marker for response. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Predictors of response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with metastatic disease at presentation who are candidates for immunotherapy, we suggest debulking nephrectomy prior to treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Cytoreductive (debulking) nephrectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=see_link&amp;anchor=H2#H2\">",
"       \"Role of surgery in patients with metastatic renal cell carcinoma\", section on 'Cytoreductive nephrectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We do not administer immunotherapy for patients with metastatic or advanced RCC. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'IFNa versus molecularly targeted therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/1\">",
"      Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992; 148:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/2\">",
"      Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/3\">",
"      McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009; 115:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/4\">",
"      Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984; 159:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/5\">",
"      Fisher RI, Coltman CA Jr, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 1988; 108:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/6\">",
"      Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889.",
"     </a>",
"    </li>",
"    <li>",
"     Sunderland MC, Weiss GR. High dose IL-2 treatment of renal cell carcinoma. In: Therapeutic Applications of Interleukin-2, Atkins MB, Mier JW (Eds), Marcel Dekker, New York 1993. p.119.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/8\">",
"      Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/9\">",
"      Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/10\">",
"      Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/11\">",
"      Belldegrun A, Webb DE, Austin HA 3rd, et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/12\">",
"      Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008; 113:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/13\">",
"      Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/14\">",
"      McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133.",
"     </a>",
"    </li>",
"    <li>",
"     Cole BF, McDermott D, Parker R, et al. The impact of treatment with high-dose interleukin-2 (HD IL-2) or subcutaneous (SC) IL-2/interferon alfa-2b (IFN) on quality of life in patients with metastatic renal cell carcinoma (abstract). Proc Am Soc Clin Oncol 2003; 22:387a. (Abstract available online at www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed on May 26, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/16\">",
"      Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Fran&ccedil;ais d'Immunoth&eacute;rapie. N Engl J Med 1998; 338:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/17\">",
"      Figlin RA, Pierce WC, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/18\">",
"      Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/19\">",
"      Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997; 3 Suppl 1:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/20\">",
"      Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993; 11:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/21\">",
"      Royal RE, Steinberg SM, Krouse RS, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 1996; 2:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/22\">",
"      Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988; 318:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/23\">",
"      West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/24\">",
"      Donskov F, Hokland M, Marcussen N, et al. Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial. Br J Cancer 2006; 94:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/25\">",
"      Blay JY, N&eacute;grier S, Combaret V, et al. [Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment]. Bull Cancer 1992; 79:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/26\">",
"      Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005; 28:488.",
"     </a>",
"    </li>",
"    <li>",
"     McDermott DF, Ghebremichael MS, Signoretti S, et al. The high-dose aldesleukin (HD IL-2) \"SELECT\" trial in patients with metastatic renal cell carcinoma (mRCC) (abstract #4514). J Clin Oncol 2010; 28:345s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/28\">",
"      Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11:3714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/29\">",
"      Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/30\">",
"      Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999; 17:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/31\">",
"      Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/32\">",
"      Bangalore N, Bhargava P, Hawkins MJ, Bhargava P. Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann Oncol 2001; 12:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/33\">",
"      Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/34\">",
"      Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/35\">",
"      Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/36\">",
"      Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 2002; 16:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/37\">",
"      Numerof RP, Aronson FR, Mier JW. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol 1988; 141:4250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/38\">",
"      Mier JW, Vachino G, van der Meer JW, et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988; 8:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/39\">",
"      Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985; 135:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/40\">",
"      Hibbs JB Jr, Westenfelder C, Taintor R, et al. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 1992; 89:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/41\">",
"      Epstein AL, Mizokami MM, Li J, et al. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003; 95:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/42\">",
"      Gallagher DC, Bhatt RS, Parikh SM, et al. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res 2007; 13:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/43\">",
"      Mier JW, Vachino G, Klempner MS, et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990; 76:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/44\">",
"      Vetto JT, Papa MZ, Lotze MT, et al. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 1987; 5:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/45\">",
"      Trehu EG, Mier JW, Dubois JS, et al. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin Cancer Res 1996; 2:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/46\">",
"      Du Bois JS, Trehu EG, Mier JW, et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997; 15:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/47\">",
"      Margolin K, Atkins M, Sparano J, et al. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res 1997; 3:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/48\">",
"      McDermott DF, Trehu EG, Mier JW, et al. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin Cancer Res 1998; 4:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/49\">",
"      Kilbourn RG, Fonseca GA, Trissel LA, Griffith OW. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine. Cancer J Sci Am 2000; 6 Suppl 1:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/50\">",
"      Samlowski WE, Petersen R, Cuzzocrea S, et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med 2003; 9:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/51\">",
"      Lee DS, White DE, Hurst R, et al. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Cancer J Sci Am 1998; 4:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/52\">",
"      Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/53\">",
"      Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/54\">",
"      Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/55\">",
"      Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/56\">",
"      Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; :CD001425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/57\">",
"      Cameron RB, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 1988; 48:5810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/58\">",
"      Iigo M, Sakurai M, Tamura T, et al. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 1988; 48:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/59\">",
"      Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/60\">",
"      Sznol M, Mier JW, Sparano J, et al. A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b. J Biol Response Mod 1990; 9:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/61\">",
"      Bergmann L, Fenchel K, Weidmann E, et al. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Cancer 1993; 72:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/62\">",
"      Spencer WF, Linehan WM, Walther MM, et al. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol 1992; 147:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/63\">",
"      Budd GT, Murthy S, Finke J, et al. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy. J Clin Oncol 1992; 10:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/64\">",
"      Atzpodien J, Lopez H&auml;nninen E, Kirchner H, et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995; 13:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/65\">",
"      Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993; 11:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/66\">",
"      Dutcher JP, Atkins M, Fisher R, et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J Sci Am 1997; 3 Suppl 1:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/67\">",
"      Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/68\">",
"      Dutcher JP, Fisher RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997; 3:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/69\">",
"      van Herpen CM, Jansen RL, Kruit WH, et al. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 2000; 82:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/70\">",
"      Atkins MB, Dutcher J, Weiss G, et al. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials. Med Oncol 2001; 18:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/71\">",
"      Rathmell WK, Malkowicz SB, Holroyde C, et al. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. Am J Clin Oncol 2004; 27:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/72\">",
"      Gore ME, Griffin CL, Hancock B, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010; 375:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/73\">",
"      Neidhart JA, Anderson SA, Harris JE, et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol 1991; 9:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/74\">",
"      Foss&aring; SD, Martinelli G, Otto U, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 1992; 3:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/75\">",
"      Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18:2972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/76\">",
"      Aass N, De Mulder PH, Mickisch GH, et al. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 2005; 23:4172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/77\">",
"      Falcone A, Cianci C, Ricci S, et al. Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study. Cancer 1993; 72:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/78\">",
"      Igarashi T, Marumo K, Onishi T, et al. Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer. Urology 1999; 53:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/79\">",
"      Elias L, Blumenstein BA, Kish J, et al. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. Cancer 1996; 78:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/80\">",
"      Sparano JA, Wadler S, Diasio RB, et al. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 1993; 11:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/81\">",
"      Elhilali MM, Gleave M, Fradet Y, et al. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. BJU Int 2000; 86:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/82\">",
"      Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/83\">",
"      Kassouf W, Sanchez-Ortiz R, Tamboli P, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol 2007; 178:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/84\">",
"      Ueno NT, Rond&oacute;n G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/85\">",
"      Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/86\">",
"      van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/87\">",
"      Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/88\">",
"      Rini BI, Zimmerman T, Stadler WM, et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/89\">",
"      Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99:4234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/90\">",
"      Massenkeil G, Roigas J, Nagy M, et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 2004; 34:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/91\">",
"      Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J 2002; 8:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/92\">",
"      Strair RK, Schaar D, Medina D, et al. Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. J Clin Oncol 2003; 21:3785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/93\">",
"      Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6:332.",
"     </a>",
"    </li>",
"    <li>",
"     Avigan DE, George DJ, Kantoff PW, et al. Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma (abstract). J Clin Oncol 2004; 22:169s. (Abstract available online at www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed on May 26, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/95\">",
"      H&ouml;ltl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002; 8:3369.",
"     </a>",
"    </li>",
"    <li>",
"     Wierecky J, Muller MR, Horger MS, et al. Induction of clinical and immunological responses in patients with metastatic renal cell carcinoma after vaccinations with peptide pulsed dendritic cells (abstract). J Clin Oncol 2005; 23:167s. (Abstract available online at www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed May 26, 2006).",
"    </li>",
"    <li>",
"     Thompson P, Fishman M, Seigne J, et al. Phase II study of B7-1 gene-modified autologous tumor cell vaccine and subcutaneous IL-2 for patients with stage IV renal cell carcinoma (RCC) (abstract). J Clin Oncol 2005; 23:378s. (Abstract available online at www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed May 26, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/98\">",
"      Aulitzky W, Gastl G, Aulitzky WE, et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 1989; 7:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/99\">",
"      Ellerhorst JA, Kilbourn RG, Amato RJ, et al. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. J Urol 1994; 152:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/100\">",
"      De Mulder PH, Oosterhof G, Bouffioux C, et al. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer 1995; 71:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/101\">",
"      Foon K, Doroshow J, Bonnem E, et al. A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod 1988; 7:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/102\">",
"      Margolin K, Aronson FR, Sznol M, et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol 1994; 15:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/103\">",
"      Weiss GR, Margolin KA, Sznol M, et al. A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. J Immunother Emphasis Tumor Immunol 1995; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/104\">",
"      Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/105\">",
"      Motzer RJ, Rakhit A, Schwartz LH, et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998; 4:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/106\">",
"      Wigginton JM, Komschlies KL, Back TC, et al. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996; 88:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/107\">",
"      Gollob JA, Veenstra KG, Parker RA, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003; 21:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/108\">",
"      Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/109\">",
"      Porzsolt F, et al. Adjuvant therapy of renal cell cancer with interferon alpha-2a (abstract). Proc Am Soc Clin Oncol 1992; 11:202a.",
"     </a>",
"    </li>",
"    <li>",
"     Passalacqua R, Buzio C, Buti S, et al. Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC). (Abstract). J Clin Oncol 2007; 25:965s. (Abstract available online at: www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed on June 6, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/111\">",
"      Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001; 19:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/112\">",
"      Atzpodien J, Schmitt E, Gertenbach U, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005; 92:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/113\">",
"      Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21:3133.",
"     </a>",
"    </li>",
"    <li>",
"     Aitchison M, et al. Final results from an EORTC (GU Group)/NCRI randomized phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (abstract #4505). J Clin Oncol 2011; 29:290s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/115\">",
"      Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/14/12522/abstract/116\">",
"      Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008; 372:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2984 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12522=[""].join("\n");
var outline_f12_14_12522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H350646872\">",
"      RATIONALE FOR IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H350646879\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERLEUKIN-2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      High-dose IV bolus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alternative schedules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IL-2 plus cellular therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Predictors of response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clinical factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Histology and CAIX expression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7375113\">",
"      - Sarcomatoid RCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Relapses after response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INTERFERON ALFA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      IFNa combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - IFNa plus IL-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      IFNa versus molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CYTOREDUCTIVE (DEBULKING) NEPHRECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OTHER IMMUNOTHERAPY APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Nonmyeloablative allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Dendritic cell vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Interferon gamma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Other interleukins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      ADJUVANT IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Autologous tumor vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2984\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2984|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/8/1165\" title=\"table 2A\">",
"      Mgmt interleukin 2 toxicity I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/51/27452\" title=\"table 2B\">",
"      Mgmt interleukin 2 toxicity II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/7/2172\" title=\"table 3\">",
"      MSKCC progn strat IFN response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/54/15213\" title=\"table 4\">",
"      TNM staging RCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21528?source=related_link\">",
"      Overview of the treatment of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=related_link\">",
"      Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=related_link\">",
"      Prognostic factors in patients with renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=related_link\">",
"      Role of surgery in patients with metastatic renal cell carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_14_12523="Cryptosporidium infection prevention in CD40L deficiency";
var content_f12_14_12523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F86095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F86095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Strategies to prevent Cryptosporidium infection in patients with CD40L deficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Drinking water should be boiled and/or filtered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid swimming in pools, lakes, and ponds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid contact with farm animals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prophylactic use of azithromycin may reduce the risk of infection&nbsp;and is usually indicated, but its long-term efficacy in preventing Cryptosporidium infection is not known",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In addition, the following surveillance studies should be done every 6 to 12 months:",
"        <ul>",
"         <li>",
"          Test the stools by polymerase chain reaction (PCR) for the presence of Cryptosporidium",
"         </li>",
"         <li>",
"          Perform liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], gamma-glutamyl transpeptidase [GGT], alkaline phosphatase, bilirubin)",
"         </li>",
"         <li>",
"          Liver ultrasound",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12523=[""].join("\n");
var outline_f12_14_12523=null;
var title_f12_14_12524="Minor congenital malformations B";
var content_f12_14_12524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minor congenital malformations, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extra nipples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Back",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sacral dimple",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shawl scrotum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginal tags",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minor hypospadias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extremities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Arms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cubitus valgus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dimples over major joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Hands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fifth finger clinodactyly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Single transverse plamar crease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bridge crease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tapered fingers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nail hypoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persistent finger pads (fetal pads)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Feet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Partial syndactyly between 2-3 toes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nail hypoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prominence of the heels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Overlapping digits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nevi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypo or hyperpigmented macules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemangioma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12524=[""].join("\n");
var outline_f12_14_12524=null;
var title_f12_14_12525="Maintenance tocolysis trials";
var content_f12_14_12525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Maintenance tocolysis compared to placebo",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"26%\">",
"     </colgroup>",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"26%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatments",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample size",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary endpoint",
"       </td>",
"       <td class=\"subtitle1\">",
"        Conclusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creasy",
"       </td>",
"       <td>",
"        Ritodrine versus placebo",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        Time to recurrent PTL",
"       </td>",
"       <td>",
"        Ritodrine significantly delayed time to recurrence and number of recurrences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brown",
"       </td>",
"       <td>",
"        Terbutaline versus placebo",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        Days to delivery",
"       </td>",
"       <td>",
"        Terbutaline significantly prolonged pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Holleboom",
"       </td>",
"       <td>",
"        Ritodrine versus placebo",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        Recurrent PTL during oral treatment (7 d)",
"       </td>",
"       <td>",
"        Ritodrine significantly reduced recurrences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lewis",
"       </td>",
"       <td>",
"        Terbutaline versus placebo",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        Prolongation of pregnancy &gt;7 d",
"       </td>",
"       <td>",
"        Terbutaline significantly prolonged pregnancy in women recruited &lt;32 weeks; otherwise, no benefit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valenzuela",
"       </td>",
"       <td>",
"        Atosiban versus placebo",
"       </td>",
"       <td>",
"        512",
"       </td>",
"       <td>",
"        Time to recurrent PTL",
"       </td>",
"       <td>",
"        Atosiban significantly delayed time to recurrent labor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carr",
"       </td>",
"       <td>",
"        Nifedipine versus no nifedipine",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        Days until delivery",
"       </td>",
"       <td>",
"        No benefit with nifedipine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parilla",
"       </td>",
"       <td>",
"        Terbutaline versus placebo",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        Days until delivery",
"       </td>",
"       <td>",
"        No benefit of terbutaline either in prolongation or number of recurrences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rust",
"       </td>",
"       <td>",
"        Magnesium chloride versus terbutaline vs placebo",
"       </td>",
"       <td>",
"        205",
"       </td>",
"       <td>",
"        Days until delivery",
"       </td>",
"       <td>",
"        No benefit with either magnesium or terbutaline in pregnancy prolongation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guinn",
"       </td>",
"       <td>",
"        Terbutaline pump versus placebo",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        Days until delivery",
"       </td>",
"       <td>",
"        No benefit with terbutaline in prolongation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        How",
"       </td>",
"       <td rowspan=\"2\">",
"        Terbutaline versus no terbutaline",
"       </td>",
"       <td rowspan=\"2\">",
"        184",
"       </td>",
"       <td>",
"        Re-admissions",
"       </td>",
"       <td rowspan=\"2\">",
"        No benefit with terbutaline in re-admissions or pregnancy prolongation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Days until delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lyell",
"       </td>",
"       <td>",
"        Nifedipine versus placebo",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        Achievement of 37 weeks of gestation",
"       </td>",
"       <td>",
"        No benefit with nifedipine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sayin",
"       </td>",
"       <td>",
"        Nifedipine versus placebo",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        Days until delivery",
"       </td>",
"       <td>",
"        Nifedipine group has significantly longer days until delivery and greater gestational age at delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Roos",
"       </td>",
"       <td>",
"        Nifedipine versus placebo",
"       </td>",
"       <td>",
"        406",
"       </td>",
"       <td>",
"        Adverse perinatal outcome",
"       </td>",
"       <td>",
"        No benefit with nifedipine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     vs: versus; PTL: preterm labor; d: days.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12525=[""].join("\n");
var outline_f12_14_12525=null;
var title_f12_14_12526="Amino acid levels";
var content_f12_14_12526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amino acid levels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Amino acid",
"       </td>",
"       <td class=\"subtitle1\">",
"        High in plasma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Low in plasma",
"       </td>",
"       <td class=\"subtitle1\">",
"        High in urine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alanine",
"       </td>",
"       <td>",
"        Disorders of pyruvate metabolism, urea cycle disorders, mitochondrial disorders",
"       </td>",
"       <td>",
"        Untreated Maple syrup urine disease",
"       </td>",
"       <td>",
"        Disorders of pyruvate metabolism, urea cycle disorders, mitochondrial disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alloisoleucine",
"       </td>",
"       <td>",
"        Maple syrup urine disease",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Maple syrup urine disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arginine",
"       </td>",
"       <td>",
"        Argininemia",
"       </td>",
"       <td>",
"        Argininosuccinic aciduria, citrullinemia, ornitine transcarbamylase deficiency, carbamylphosphatase deficiency, inadequate diet",
"       </td>",
"       <td>",
"        Argininemia, cystinuria, lysinuric protein intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Argininosuccinate",
"       </td>",
"       <td>",
"        Argininosuccinic aciduria",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Argininosuccinic aciduria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspartate",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citrulline",
"       </td>",
"       <td>",
"        Citrullinemia, citrin deficiency, argininosuccinic aciduria",
"       </td>",
"       <td>",
"        Ornitine transcarbamylase deficiency, carbamylphosphatase deficiency, inadequate diet",
"       </td>",
"       <td>",
"        Citrullinemia, citrin deficiency, argininosuccinic aciduria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystine",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Molybdenum cofactor deficiency/sulfate oxidase deficiency",
"       </td>",
"       <td>",
"        Cystinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glutamate",
"       </td>",
"       <td>",
"        Improper sample handling",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glutamine",
"       </td>",
"       <td>",
"        Urea cycle disorders/hyperammonemia",
"       </td>",
"       <td>",
"        Improper sample handling",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycine",
"       </td>",
"       <td>",
"        Glycine encephalopathy, organic acidemias",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Glycine encephalopathy, organic acidemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histidine",
"       </td>",
"       <td>",
"        Histidinemia (benign condition)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Histidinemia (benign condition)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homocystine (free)",
"       </td>",
"       <td>",
"        Homocystinuria, disorders of vitamin B12 transport &amp; synthesis",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Cystathionine beta-synthetase deficiency, disorders of vitamin B12 transport &amp; synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoleucine",
"       </td>",
"       <td>",
"        Maple syrup urine disease, fasting",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Maple syrup urine disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leucine",
"       </td>",
"       <td>",
"        Maple syrup urine disease, fasting",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Maple syrup urine disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lysine",
"       </td>",
"       <td>",
"        Citrin deficiency, hyperlysinemia (benign)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Cystinuria, lysinuric protein intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methionine",
"       </td>",
"       <td>",
"        Homocystinuria, citrin deficiency, liver dysfunction",
"       </td>",
"       <td>",
"        Disorders of vitamin B12 transport &amp; synthesis",
"       </td>",
"       <td>",
"        Cystathionine beta-synthetase deficiency, liver dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ornithine",
"       </td>",
"       <td>",
"        Ornitine aminotransferase deficiency, HHH syndrome",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Cystinuria, lysinuric protein intolerance, ornithine aminotransferase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylalanine",
"       </td>",
"       <td>",
"        Phenylketonuria",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Phenylketonuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proline",
"       </td>",
"       <td>",
"        Hyperprolinemia",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Hyperprolinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serine",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        3-phosphoglycerate dehydrogenase deficiency",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Threonine",
"       </td>",
"       <td>",
"        Citrin deficiency",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tryptophan",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tyrosine",
"       </td>",
"       <td>",
"        Tyrosinemia types I &amp; II, hepatic dysfunction",
"       </td>",
"       <td>",
"        Phenylketonuria",
"       </td>",
"       <td>",
"        Tyrosinemia types I &amp; II, hepatic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valine",
"       </td>",
"       <td>",
"        Maple syrup urine disease, fasting",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Maple syrup urine disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <strong>",
"      Patterns of abnormalities:",
"     </strong>",
"     <br>",
"      Argininemia - elevated plasma arginine",
"      <br>",
"       Argininosuccinic aciduria - elevated plasma citrulline, elevated plasma argininosuccinate, low plasma arginine",
"       <br>",
"        Carbamyl phosphate synthetase deficiency - low plasma citrulline, &plusmn;elevated plasma glutamine (identical pattern to ornithine transcarbamylase deficiency)",
"        <br>",
"         Citrin deficiency - elevated plasma citrulline, threonine, methionine, lysine, and arginine",
"         <br>",
"          Citrullinemia - elevated plasma citrulline, low plasma arginine",
"          <br>",
"           Cystinuria - elevated urine cystine, lysine, arginine, and ornithine",
"           <br>",
"            Glycine encephalopathy - CSF:Plasma glycine ratio &gt;0.08",
"            <br>",
"             HHH syndrome - elevated plasma ornithine",
"             <br>",
"              Homocystinuria - elevated plasma homocystine* and methionine",
"              <br>",
"               Hyperprolinemia - elevated plasma proline",
"               <br>",
"                Lysinuric protein intolerance - elevated urine lysine, arginine, and ornithine",
"                <br>",
"                 Maple syrup urine disease - elevated plasma alloisoleucine, isoleucine, leucine, and valine with perturbation of the normal 1:2:3 ratio of isoleucine:leucine:valine, low plasma alanine",
"                 <br>",
"                  Ornithine aminotransferase deficiency - elevated plasma ornithine",
"                  <br>",
"                   Ornithine transcarbamylase deficiency - low plasma citrulline, &plusmn;elevated plasma glutamine (Identical pattern to carbamyl phosphate synthetase deficiency)",
"                   <br>",
"                    Phenylketonuria - elevated plasma phenylalanine &plusmn; low plasma tyrosine",
"                    <br>",
"                     Tyrosinemia types I &amp; II - elevated plasma tyrosine",
"                     <br>",
"                      Vitamin B12 (cobalamin) processing disorders - elevated plasma homocystine* with low or normal plasma methionine",
"                      <br>",
"                       <br>",
"                        * Routine plasma amino acid analysis measures free plasma homocystine, not total plasma homocystine. Total plasma homocystine is the preferred test for the diagnosis and management of homocystinuria and disorders of vitamin B12 (cobalamin) transport and synthesis.",
"                       </br>",
"                      </br>",
"                     </br>",
"                    </br>",
"                   </br>",
"                  </br>",
"                 </br>",
"                </br>",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of V Reid Sutton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12526=[""].join("\n");
var outline_f12_14_12526=null;
var title_f12_14_12527="Pulmonic stenosis Doppler II";
var content_f12_14_12527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary valve stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 217px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADZAPEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAFFLSCloAKKKKACiiigBVUswVQSxOAAOSa9Y8N/C6O40e7j1N3Os3FsZLRYmPlwHAZd/GSxIKnGQA3GTyuH8L9Cim1X+0r8x+RZjzSjHJyQdgx/eJHHIxjPavSbLxglvr2+7VwSwMpiJO7v0OB6dP/AK1bU0o2cuv5df8AgfM56rlK6h0/Pov8/kcjeeENM8P+GvC8niHSTGb2edb7UXmf93tLhERAyjkAHJH4+lb4beEtJv8AXNIs9RS31VtQyZbZWkjltYvIEgl3LIAMNxgg5GMcsAOu+J1il6stpaLLbwPh1k89trggYwo6jqMHPTtXiDzajpzSQGe5t9wwyrIQGA47HBHGPwrOUXCTi90bQmqkVKOzKNFFFSUFFFFABRRRQA2iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAUUtIKWgAooq3/Zt6dNOoC0uDZKwVpxE3lqTwMtjHJBA57GgCpUtnDLc3cEFupeaV1SNR1LE4A/Ooq0NIVN07CdIrwKottxCguXUZ3HhcKWOSRjrnIqoq71Jk7K6Olg1G2gay0+xOYbc77iQt/rpxnJDjqgHCj3JIBY110dppF5o89+8FyixPtNwjgpn0w3JPOeD39K8sGn38NlDfNZ3KWb8rcGI+XgNj73TqcfiPWvSdSF5ZeBdKs5ZI/Judl00YBEjAjIOc4xgA89yPSs8R7bSUI6XV/KJdD2N3GT1d7d2/wCv6RvQm08ReHbKT+0beC7jhZGluHIAwxwCxJwNqlscnqQMZx5Zr1vGzufO8xQW2OoYK3J5UEA4PPUD8+K7zQLjSLUtborXFu0X2h28xyvmD5XBG3H+qMnIzk4AINed608ltf3UD7FMUjIwjbcuQcfKehGent610TnGrTjUivJ7nLTpzo1ZUpvzWxiMpU4IxSVKULK5VWOOvy/dAq1o+j32r3clvYW0krxxtNKVUkRxr1dsDpyPckgDJIBxOkoUU+aKSCVo5keORThlcEEH3BplABRRRQA2iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAUUtIKWgArQttPbG64UgHjb3H4VXtAgcM+M5G3nnP8An/JrsdMW1v7VorjbFcLjY56ZHUE9RwPf+tAHK6hZi3YEknnBI7+/1qoEBYcriu31HTm8lh5TKQBvdQG54/D8ax59LuYIWb7O5jBwDtJK/l2/ligCXw5eyadcpLbXFzCSTlopCpPHf16nr6n1rqYPFcrrJHc29rPGCSgltIpCpyAMFk9OOe1edOGQADAwB1OM4788Z/zz2EYyDY0uAM4JIPb0/wAKuNScVZN2M5UoTd5RTfodPq/ijUpbcwSXsyRn5jGpIRsk5JUYB64yRyMdgKz9YtzN9gvoyrJdwrvSJQDHInyMpUdGO3fjjhhgelVLCSSJTliDjBCEn88frXXeGdGW70y4025uNq5F1BGq5fcow3OOMoSeo+6o5qoyc7qTvf8AP+tCZRVO0oq1vy/rU52TS3FlA8Q2luQvUr7/AFrGns2Xe+MKOuOgr0bX3tFj26fGsdsECKSCXfHG49Ae/J/XFcJqU4d23k5HQE8D6AYz/n8MjYyCCDg0U6Q7jnI/Cm0AFFFFADaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBRXR+GPDtnrFneTXniHTNKeIEQxXRbdM+M44Hyr/ALR/KucFLQBbQmOR4xsdVOC6/dOO+fT3rW019ib41kByAdoxgeh9q56tTSbxImIdvKfGFcDt0waAOvgmuAoaVyVI+dCAcjjGR9Tn8vTFXIpoQAVBwM/u92evqDjP05rCjvSWT98545IOcHP+ef8ACrn2jAYOxI7jnn8T06f0oA1rO10G4dDfW0hdiR8pITPXoB9DwQf0FbcqeG1t1htbaAEvhZlwc+nJGR/nmuJmlljbPmyYOeA5/qacs2yMMJpAhwcEDH48UAbF3aRo0zKbcNtyFMgIA7Fj+v41RbVLhZY5oZE85G3ARKARj1I//Vz71nrqMSSu0cMUjHs2c5/T+VNeO/ubvFqlw7dQLZOD7Z9vpQnbVCaurMPEKt/adwLWAwWjndHAxBZEI3KHIJ5AIHJz685rn77aWbswGBg4z/h+nSu61TRFj8OWTziK0miJt58AmRySXDOvA5yV5OcKOOw5S5uLPT8LCiyPjknkj2xx7Vc0r3WzIpP3bPdaf1+ZjSQtyzqwVeP8/wCf8K09L0O1vfDuoajLrdhaXdswEVjMWElwoUlipAwD90AdznkYGcy9vZrx8yt8o6IOFH4VWqDQKKKKAExRilooATFGKWigC7b6Xc3Gk3eox+V9mtWRJMyLvy3TC5zj3xin6NpFxq0lwsDwRR28XnTTTyBEjTcqAkn1Z0HGfvfWrGma4LHQ9Q03+zLG4F7jfcSmbzEx93btkC8H5hlTz1yOKr6Tq91pGoLe6bJJbTqhQNBNJGeVxncrBs5564z2xxQBel8I6uliL2O3E1gYZbgXUR3RbI5GjY7v95eB33D1po8L3i6tcadcTWlvcQ3EtqfNlwGljZVZV45OWGPXmpNU8X6vqgiF7cb1VJgyDKpI8rzO0jKDt35uJACAMDAx1zo/8LC1eXxCdZv44L+7Vp2gFxJPttvN6iIrIGQLztAPy5JHOCADmtb0yfRtXu9NvDEbm1kaKXy3DqGBwQCPQ8VSxU95Mk9zJLFbxWyMciGIsUT2G4s35k1DQAmKMUtFACYoxS0UAJijFLRQAUUUUAFFFFAEkU8kRHluRjt2/Kr0GqujfvkDr7cGs2igDbOrpK5Ll1GOhUHv0zU8Op2wJaSXc2eN6Zx+n1/xrnaKAOsbXrJQCqAtjnEQ/TpVz/hYF1bQNDZREqevmkYIHT5RxXD0UAaeoa7qN+7m5uCwfBKgAAY6Y9x0B64JHQmswkk5NFFABRRRQAUUUUAFFW4LB5YVlM1rGjdN86g/iudw/EVPDpE0s8aRPFOCwDeS4YqCepHXHv06eoqXNLqZutBbszaK6rVbaz1OW3u4w1nYRzNaTzRx+YsSKRtcqME5DevbA564kOlXDxRyymK3ik+400gXcPUL94j3AxUxqJrXQmnWjKmpy0vpa+t0UKK0jpabS66jZMgOGb94MenVMnPtmmjTQfuXtm3Y/ORg+nI5/Diq5kV7WP8ASZn0VrXOkRRrbmHUbWRnj3SKx2+W24jb3yMAHPHX2qFtPt8AJqlmXxypEgwfTO3H45pKaY3Uinb/AIP5GfRWiNK3HCX1izenm4/UgD9amj0ZPsU8lxqNnDcKyiKESrJ5gOdx3KSFxxweuaOeKCNSEna5kUVof2WdpP2uzwMc+b6/hR/ZUzHEc9k/b/j5RefTDEGnzoXtodzPorZ03w9c6lexWlncWTzyMEC/aFHJ+vX8Mn0zRqnhu903ULi0nksTJC+xiLuMAn23MD+YFL2kL8t9TT/l37X7N7X6X7GNRWgdIue8ll/4Gw//ABVJ/ZNx/wA9LL/wNh/+Kp88e5n7an/MvvKFFa8+i7EtzFfWblo90waeMeU+4jbwx3DG05HHzdsGoTo9zu2iSzJzgYvIuf8Ax6kpxfUHVpp2cl95nUVfOkXecL9nc99lzG2PrhuPxqxb6Lvt7ppr2zimRA0Mf2mJhKdwBG4PhcAk89cYoc4rqCq039pfejIoq+NJn/jnsVXuftcR/QMT+lX7LSvJjvUvbffP5i2sPzEDe38QI64+U++feh1IoiWIpxV73MGiri6dONSjs51MUjMA2edq92PsBzn0qze6K8N5PHb3VlPAjsscv2qJPMXPDbS+RkYOKbmk7NmrnGKu2vvRlUVf/sm47S2R/wC3yH/4ql/smc4CzWTOedouo+Px3YP4E0c8e5Ptqf8AMjPorYudFSK1tJBqNk00isZY/NU+UQxAGVJzkYP44qt/ZchyI7mzcjqPtCrj8WIFJTi+o3VguqKFFaP9jXeM7rPGM/8AH5D/APFVd0jwrqWsXMVtpiw3Vy8yQmKF/MKbs4diuQEGDls8d8U+ePcI1Iydou/oYNFd1/wqfxl/0Brn/v23+FFUWcLU9rc3Fq5ktpnjcjaSpxx6H8v0qEDgnGf6UbjtYZ6nJoavuJpNWZPBdXFpI32e4liYfxRsVOenY/hUn2qSWR5pppZHOfndstnHy5JqBclthBZgScDnPrTo4mnlWGBTvOflx6c0rLcOVX5raiFmWIZBw3Uj+L15/Ko1HzLtOT6AZq1BFJMrKEG1W+9yAATg59qsWunsj7rglQCFUjscZpjKsozGHZVZ9/G3kEVESjEvJkkjAA7nH8q1JrDy7uExI4tu7fXIzS3WkmG4dGkVijHJAz69vTj9aAMcrl8BsnoD7VM8LR2sUjr+6kdgrd/lxkfqKluIybiVYflTcVz24HT+n/662vEWky6Z4e0O5ucn7Y07iMjG3AjH49etAHOLlsKhI5Ht+J/OgOwAA2/KfXr3/GlU+TISyA9sHtRsO2Ms2UY9uoxQA0MRyNoZTnI60pYnJY5OOjCn2nkieNrlZDApG/yjhseozxTZ9vmN97Pv6dv6Ur62HbS4m/YCqEFeD9T6/qalEirbsrAMx2lQDwO358/57QMo3ELzgfn9Kd0UsBwQB/n8qYg35DZGQec470jNkA7ucYwPoKE6leCCQM0mAuM4Oe3SgB8ZQKefmIxz0FMAycAE5HYc0uVCjGAfr0xRyoDD1wCP8/55oATBXaWAIPT3q5PqF1Nb2sUlxuSDBjA4K4wByOSeAPYDiqpVnI3HBbnn0poUbV7Fj1PQUmk9yXFN3aNnV9eu76e4lS4eJJcqY1PbjgH0PPHTr61kEFyOBuYZ45z1q/rlm9nqlxZSoFmgbawUcZzz/PrUK24GTK+1FwuV5GSP5f40JJbBGEY/CrFLOOlWFjlKkLhQqeZ1xgdP1zV+90mWBrbaP3kitIcnGPmOOasHTXmu3GCqHhQOvUA9O3X8qZRihWkXeM78ntjPf86WFvLUtlSPQ+uOP8/Wul1vRY4Qz2JPlJKYdp5OMFs/SsFrGWKVVmCjeQM54Gc+3tQBPo8H2wX+/AENpJKOO4xVK1vJ7S8gurWQxXEEglideqMCCCPoQK6jwnpUtxca/a7SXh06U5ToSMY/PNctMsaxjCsHPfPGOc/j0oA0f+Em1n/oIz/nRWRRQAqggFhjHvS52kjjIyMitaw0Ga+tYpkvdMhR88T30UbDkjlScj7o7fxD3xZj8LXLDB1LREyqnnUoe+eOG6jj26de2bqwTs2bxwtWSTUdyjoGlXOraxZ2dooM0zZAzjCgZLc+wJ/DivQPAHgy6j166fUQvlJbSgbCwLMysuB3yOenrwasfCjQp7LxFY3zLZ3K25Ys1teRy43ow24Unp/XjpXrI8R6RbalJbyzW8Lsc83EQJx2xuzng9qTrQXUawlZ/ZZ55Y+Ap4bSG3AjYqD5nueMY4556cdvepJPh1JDCkAO5UYTZ5yeowfzBr0y31zTZfm8yNjjj94h+vIPb+tN1TxHpkBbdNbrjOFeZFznoOT16fn+R7aHcPqlb+VnI2/geMSMGjR0HyqCSB0yS3Hr+X8+P1Pw1NZPI8URknjXDI3IZQWBf9AMV6tN4p0xVjdZYMyY4E8fp7tg9/y/GszUPFOlrOp/0dlPy7zdwLkZzxl6Pbw7j+qVtuU8iu9CuINQFtPbCIzqJIwoPBYt8vt/9avQPiD4SmvLLw7aW25zarPl8cceX1/DNS3fiXSpbqCTdp7LGFLsb+DIAY4/j9SPT/Hs7/xPbz6PZpp8Mc8292ws0eDuUDg5wcYo9tDuL6pW/lZ8vajoV5HdJEIixx0Axx2PPrzUGo6VeQsBJCQTz9M+v+fSvddXItdNEl7pkCTlXwZLiJARyRgswHpWV4qv9M1C306Syk0xbpGAmBv4B8ufXdz6/h68UKtB9QeErL7LPDvIkGQY23dOnTp/9emmNsHOdy5BB7Yr0KG28qR2EuiIziUDdqcOEzgADnPXJ/ng8VVl095SzC40FJWzh21KEgY47N3znjt6Hij20O4/qlb+U4YI3lsQpxkcjp/npTpAyxKHTBIBU+o/ziu0t9LK2bQPcaHlnZt39pQYAHGOvcHP09DUcOjusEUT3mis8Z27/wC04cEYzn72ccAev4c0e2h3D6pW/lONAYKrKO+M9cn0pM5J35J9c5//AF1139il0VRPoYzsB3anDxhQc8N68fX25LotEHmRO8ugBW27h/acRK45OTu79OM847c0e2h3F9Urfys5JYmfeAPmHUUwkqCpLAgnjPHvXXf2JJtjKXehBnByDqcPyk5IJ55644J59uaiHh8O6+ZdaMAypuJ1SDg4Of4s9scevfkg9tDuH1St/KzlkJyAM57H0FKg8yXAX75wAMetdSPDpkjiX7XosWMOT/akOSTnI4PUYHt6ezdP8MXD3ttsvdG3nZhF1GFmLE52jDHJzgfjxmj20O4fVK38rOh8VaSdf3atYx4guLidy20gsoRWBPHA4J/Gtyz+Hq3HhOzRFDXUoSaVzz1GcdPSvR4ZING0iO2uLZECkgfOiryMAZYjk/1qe18U6YsQhRooxGo2p58Rz2xjf+HP9aPbQ7h9UrfynD6r4LNzb2C28Wx4rd12tnHL9cjvz0qa58DsIgthGisvMPOACFCkfp+prsZfFWkqHVp7dlBxxcxD1yeW9v1qH/hLrFUYyLAMOQoF1CMr/wB98c8Yo9tDuH1St/Kzjv8AhC7ye8JcRbY08qQKxJzjORx+Fchqvh6Y30dvclmYIzAn+L5xj646V69H4x0z5xK8AUlcMbqA59/v/Wuf1XxFpUl0k0IsJJ4ZCoEmoQr8pyTn5z7ce9Htodw+qVv5WR/Cnw5IIdXu7na7SxGH5e4CjPb04/CvIfHegvol7sZcKzDaPTj+uK+h/h34p0pkeD/RkmZHZore4imPIHUKx+np7mvOPjsY5tIguI4tp+1JGxLKSMI5HQnrz+VNVYN2TFLDVYrmlHQ8VooorQwLaPHJDDHty4BztGT1z39qjYxhgdowOPbimQnEilfvdOelOX5WWU8Kxx159zQB9Dfs16xpkdjf2FwsfmxO0yqeC3HPB9ABXcXEdldFLg28UhBO1jjKj2Pevn74NXsNl4qsDv2yTNOkgH9wQkj36g17jFdxTMgVx5K5EZTjv0Pt0oA2YbiziaONDFyOFDYyAP8AAipJ2t5XJ8tG6EHA4I/z+lcrPO8E05ij2jsGHJXb836Uy2vSJ7gtMTFGp6DoucA/XmgDqn+zGGGVURhjC4A4+npVPVksH2w3EcLFV3gFc9iMjIrEur2NtAiVnaJ441Y4OCSeP6mqeo6gHm07a2D5YJyevUYP5/pQBDri6PbhiLCCdSFyyqvK5zj88evauzF3Z2lnbE+TCrhSoJA6+x7V4j4gvjZbvKuy2S8hJ6Bef55p/wAQvEjLpHhmQZbz7J39id2B/WgD2a+1HTdctZIojA0SxkFhjGOckHvXnmuanosi30NrbWhljQeWxK5z/e47ZOPwry2XxbdxWogtpPLiEbKAvXcT1z3HP6VgSX8kkrTZKl8B+Tzj+f8AjigD0mfXdEsY4bSSC3KIoDsoBIXA4x67v88VWi1zw7b2o8mzidkZXk3gAnq2MHr0x3rzXziT82ecE44wf8inLMo38YJGAfw/z+tAHXWV7o0EFzut4WmKBCGX5eFI6/Udqzf7QsobWSGG2idJJBlipyMf1rCEo2NxgDovUUK7YO5wRngk9/XH+f6UAa95f2QuEEVsg2hUJ29MdevWrUmsabNE6ppyK4H3towemf5dK5s7jjDZ9/rTwFVuvyHjr145/LNAF+a8shI5htUCkNjIORnp+lRRTW67JPJUsrYwAefX+n51WUqQH5XaACAcd+34Ux2Db/myOMDoPyoA0Ybu3RJd1qkm8Kq5HTGfTvg4re+HGrWOmeN9MvJ4lWETkYIPG5SoGfqw/wDrVyJxsHIYD1ODjHSlhcxyqzYJQ/dJ/WgD7p8XS6dPcW9xZCHyJIhKSMEAnkewrnoRCoc+Uqgnv6ZOOnqa5LwVq51Pwdp0bEtOEZE3EEvswAf5VqWc1xFCqXauSFCsVU5yPQfh/KgC7exWMuXaKJvPYJuAB6H/AD0q3GtoQU2xHb16cZ/yPyrm5pmKW7tuRBnjrg4/p0qrZ6vE95MyLhjhCucZO70oA6p7eyER8xINnUlgMdc1z+rPpNhfGJrKAySHAwi8nv8AzFZ+rXo/sEW7SjfKm0tnktgH/P8A+qsTW7/dqlzDKihVyyO5+6VJOc/7p/SgDq/Bq6dbXF+EiiSQOHfC8jP/ANcH/Oa5f4/3tvceCbRImRn/ALRRuCDwI5f8RXH6V4vmisNblmUxS3MX7sYOA2QB+ZP6VzHizWzqdkiNxmRJQA2R9wjp+P60AcrRRRQA6NipJXAJ+lKWJPznHfp605VVY1cnJOTwelJIpUfKRtHGR1ORmgDS8M3MlrrdhJat5c/nLHnAbIf5WGPoSPxr13wpLI0yTzNueBjNMFzyCBtH1HNeOaVLImo2zRHDqwK4/Ufz/wD1V1v9ouWuIIn2JJIXm5xxkcA/if8APUA9amjfUpobkpsZtqc9GGM/z/z6R6tby+dvVQzCAK46bh/L0rhzf3IktLazJNsowWfPPB7/AI1ovfS3N2jqxAtlWMYJO1gSrH6Yx+VAGxeTSKHhMZDCMKFKk5Azk9Px/H8ayb0RwQWsh8xoViDd8E7juz+v5Vf1Ge1ja5nldmlFujlwfXavFctr+rC6sHhkO9LhQFYL0PU4/HNAHK+L9Qa4vVxJH5T5I2HI2hjjj6AVQ1zU5NRs9JWRj/o0P2cYPAwxP/s1Q6o+4xKxXy1BVRkZI5I/nVKUBljAUhskE++BxQAyUhioRRhR0HQ+9CAgjcQFzg8Drj0p0RdsjLbtp5+uP6UTSEkgkbQ3QDt60APsriS0uVmtJNsyfcO0c546H60ySZnLyEje4weB3znillVFC7WGxh9cc9f51GhYEmLI+Xk0WW47u1hTt4IYEnLEHv6UmQQOSrEcse9TRfvZnO8KTkj/AOtUKEHysE7g2MYoEIpIX2GfwzxipGIMYO4EKcHHVv8AOKaCpBGSckk8/wCfSljOd4X5VODjvkelACnYjSZHOMAA+oqNWU5L5z7Hr/ninyLmchWLHb2+nT/P0pqsF+ZWbcAMA/rQAgfIUE4ABHA9qcfljbJJZj39f8mnOCS/OI9xxn/PpQi4TDk7WI4H+f8AP5UAewW9wbDWnks4M2kE0whcN1YhRgV3+ja3DdTfOybmbC+uCOc/jXhXhzUDJYxWsuWALsWOT1A/wrd068ksLwzwH/R4ATt9TjGR2z8woA9kuFSa3uAI8CNiEUDJcAdSO/WuPu7Ipc3F6ATOAZYogeAN3X9SaLTXQrWbxkPNxJcn/ZOcgfRscelXpr9LWDF3IroJiMDGDGc4Hv25oAxpvKgnhTyg73cUZLKpKq4C5z6DjNcv4+nRUgtIw8YjG9XHGQQQT+Y/Sum8UXZttJF5BIkkyFEB7bSOv6V5lrN406QoitifcMMckKOM/nmgDGnfyzcAuWYrsbB685/PIqvLKTH5e7OMZx904zj+Z/M0sxxIQ+QSAMjgDjFaHh2DSp9as4fEt5cWemFgsstvGJHUZ/l7gHHoaATsY9Fe3/8ACO/Br/oZL7/vtv8A41RQB4koBGTwB3p84ZZMuqgnnbn+dEfRS2No6YbBz2oK75OeSBjH0H/1qAJLeRDeRkR/L5gwAcd+K6p0SIi7nYlSu7r0bv8AXP8AntXKoBGYnDZbIPA64NdKjr5kUFxMZQY1lRyB1OMg/lQBbsbh47gxF3wFAjy3Xtg+3FMTUbq2iuHglKncyyIzHG7J5/E1AVdTvRirCM2+3OMkjGQe2D/WqEYg8vyzMVunkPmMTkHA9PQ/59wDUh1abEguXllcW5ZnY5IAI+XH+HrWfeXshSNppfNHlBCoPQc/0qEzrNeJvRlWXOeMAjOP5jj8Kr31qIo0CsNoUgdu/bvQBnuyvcO7KQCc884J9f1q9o2k3us30OnaZYz3uoTljHDbpudwFLHAHoFY/T6VnzOZHYnBJO4kV33wH8R6d4X+Kmg6vr919l0u08/zZtjvt3QSIPlUEn5mUcD9M0Acpr3h7VvDtytrr+mXmnXTJ5ix3ULRll6ZGRyOD7ZrL2kfMRx05Hb1r3Dwj8UNAl1mxg1bT4dJ0vTdJmsdJkYvdG1md1cyO2C/IBG5VyueB1rotB8feDrfxXq+rTaxZW8txJZB1gspxa3KoGEpAEXmF+ehCIxOSD2APn+TSLu20yw1m8spBpF3M0UciyBfNMeN6g8kHkckd+9UJmR3YRBlTqoPJ+navo2Lxx4BXS7mwF3HaPJfaw+m3gs5Gi09ZmHkS+VsyQyrgYG5M9B1HA/A/wAR6L4c1TV3166s7ZbmKOOKaSKbzVG8ljDJHG5Q47FcMDjIxyDvpY8vCgDJAwDhuuTT7e0luZoIII3knlIVI413M5JwAAOSTnA9TxX0Tp/iDw+/gfxd4lW2a5bRdSuItDu7mCNGna8XbhlUBSyYaToMAjgdKrr8RvCtl4S8OJBqSLqWny6efs2n2jhGEbqZmlSSLCvgH5o5GLN1wM0CPn+6tp7K/lt7yCSG5hkMc0MqENG4JBVgeQQQQQec1rW/hTWriysLpLLFtqHntayvKiLJ5OPN6sMbeOvXtmvcY/iD4YfxTr11/wAJLZxyXOuRX4v/AOypHFxp2W3WW3y9wbkZJADd271n23jrwVnw7G8iW9laNr7tayW7uLZbk5tk4UgnoMjO0rzigDwNCsbhg27HYZFClWYgKMsMD2Ner+I/EukXfw30+w0XW4NNih0uG3utFbTWaS5ug+Xm83aV+b727eCAu3HJrykMuVx8u0YyCeaAGuQCAQdykg5/QVI0YKqS38Ixjv8A401xtiwCeG5/p/X9aaFJK915xz/nFAGpaCa1u2WCUO5wSOxX19+prYjmuWYybj9ljRlZS3QEH+X+FYVtPIt28oYMHVkBceoP61olriCELtVY/IZ9rDIbjnI78/560AaTTywRbFmcu8gjOe467fp3/E1qPrbxW85kP7xZmQHOcfKSTj8q57W4YLRi8LyCRmR1y3UYBz9f/rVHqdvMge4U/N5hQpnqMEZP4fyoA0bnV5bvT4oWmMaeWr7QxIxxgfhXMzTyxxD5iSMqGycjPOR/n+tXmLbFkUpuYDehA/Dn8P51QviDICygSFTn68/0/WgCs6jdui5UHjjqfSkkQpGhORnPBpCCoyVBBXgge+M0+dCsURbO4g5yc45//XQBDRRRQBNGgIU4BBB7856f1FNMf3hkBlO3j/PtXXRa6B8PTpP22ZWG5ltUWRVZvNV9zESbGACnqmQcY9RB4W1O20LVbh4NUuIFmt/LW7hWRDuJRiDsZXAyrDIPJ9qAOWLZAbB3Z+9/n8K67Q44rrT4HYrugLgYUEvwAufb/GtQ+J7KW+lmtte1TT9O+2Sztp6RHbcZmZ1Z1VgnKlFPXG3gHABZF4kW/wDD9jZwWlpbX8U9zI4giMaMXWHDFc4yXRuAABgBQAAKAMEozee8z7Y1BRVJxjLe/fGeadLalLG3vY5B8sgUqRkgkcn3rWvoYLzcwwrBFn+cZG3OT+A55rNupfKM8TqPJ5KNg89gOP8AP5UADxBpIWWRR8gUBxgkDkj8+9ZUm9klWUvuzgJ0CsMDd9OP84zV6SRiJXuQihUAAQ/jx+X+elZcpmLSPISHdsexP09f8+lAEUSx+VNuc7gQAR0x0rZ8BeGpfF/iKLRbW7S3up45HtxIDiWRELCMehbBAPrisIMACobCMeVHp9a1PC8usQ+INPn8NRXMusQsJ7YW0RkkDRgtkIAc4CknORgc8UAehab8Gry7u5lu9Xt7WK00+zvL4iFneB7nJjhKZGWwu4nIx7nitGD4QLPosGmWl3aS68fE02mnUI5maD7Mlms5YAcdMtwM9q5S68VeNdNuW8XT3j7PEZkR5ZooZYr3yioYNEylMKSoGV47VQb4g+KNlq8GqmFor46khggji2XPliPcNqjA2ALt4XHb1AN+0+Ez6jc6fPp+vWcnh260641L+05omi8qKCTy5d0ZOdwcgDnHzZyK1vDfw20TV49DjbV47nTb3xENKbULcSRzEfZlk8sI25Adx27sHk5yVriZ/iB4rOs2+rjVSl1bwNaRrHBEkSxNndH5KqIypzkjbg984pb34h+K5vsrPqqotrepqMAgtYYljuFjVFZQiAABFA2/d45HNA9LHT2fwhOtXl4fD2uQT6ZaanLZXM8sTr9lRYTL5sgIHy4V0z3ZeOorj/AnhI+LNeuLBbqS2hgheZ50tzKFVSBlhkBRz95mAHr0FdO/jbxLoOgeI31ayZb3xraQut9GY4Y/IVmViIY1C5cBlz8p+8cEnNcZ4X8Tar4WuLi40S5ERuYDBMrxJNHIhIJV0dSpHA6igR2+sfCMaBd65Jr/AIgtbXR9Ne2iF7FbvMZ3nTegWMHsvLEnHpmnJ8JPtF/4btbDxFplxe67teztzDMN8W5laUttwFARmwTuPTFYL/FDxcdQu9ROqLJNeLFHcLNZwSRSCIAR5jZCmVHQ7c9aoXnjTxFqWs6ZqU2qS/bdNH+iTIqRtEN5kPKqN3zMx5z+XFAHYab8I/7W1HSTpXiKzm0nVba5uLa6aFopXaB1V4kiJ+Z8upAzyMnjFW9L+CVxd3etw/2s6tptwkHlLp8rXRzEshdoMh1T5toYbskHGRgnkZ/iT4rm1YXkmoQSSxwPbJFJZW7QLEXDsohKeWMsoYnbkkZzT4fil4ygnubldY/0u5lMrTvawNJG+xY8xsUzF8qqPkK4AHFAHFhNjsrtsYEg+3BpNmE5ODxx/WlKO2ZGO4kgkseTmnorbwqkBuMEjAGO3NAEqjyLlRgNHncE98ZGf09q6A3T2dsjyYctGG3YHQqDgD8K5yR2UJKvUgE57Hjn+X6Vo7zFZJJkO87DO8nAU8kD8RigC87sl289z84BEabsD9Pp/ntVP7TLdo/mKQ1qCHOOSC3p65PSrl5MJ5pICBtVARNjGcf19Pp3qKD5J5hbr+724kY+uT0oAqTReSginLY3bhhuG64P8vasyZxKC5bktwvoK0tRDfaFn3lkcBRg9Rg45/CsxsopHIK8fUEdKAFeRlYlM+WwwAeeOf8A69OmQvB52UyrBHBcBskHHy9SODk444B6imJtC4l3AAjgd6Y33QcYyeOP60ANooooAegyRlj3GPagjd09fQ0gyu1uOQfxqQoDb7hjchw3Pr/OgBkn3cFVDbj0qe2ke3kjnLEAtggDmoCfm3Ny3UgrxTkGVLKenGD6n0oA3tPunS2ZWTeWYhNx+6p5Hb2qbUp2t7tkjWNo+XQ4zkEcDP58f5ORayq+ElcIzPnJPTIH/wBfvXffDjTfBV1qs5+IPiC7sLWN9qRQ27N5oB/ikAYr6cL07jsAcTeNPdwSzCJCoVHcxnOw4AyT6ZPfuaoYkWM7yqglcexxwf6V9w30vwxi+EHiax8JyaJNp402eaS1s7lFmmKIWXcTl92VGCwJH6V8hjX/AA2iMLfwfbSlRkC9v7iTJ9/LaPP/ANbtQByagFHf5RgY24z/AJ/+tXffA/xJbeD/AIk6dqeq3JttPVJre4lERl2B4nCnaATjeUPAzgH6HObxXHFgWHhfwzB6D7NJPjj/AKbSP/XPfNSeH9Lu/iP4sh08y6dYX1zbsLaOCzjt45GjVmVNsYA3EKQGOSeAT0oA9Y8OfE3RLB/Bmn6nrVheabHd6oNdb+zGMckUpBiKhotwVjztQA9NwGMDKtfGnhIfCaPRoG0+3uf7IltrqxubSV3kuskrOjIhUsTtIZnUrjHPSua0r4RzTa0lhe6v9lkTT7W/uHW0Z1tWn5WKUllVWAweTznAB5rcX4SW6aWukXF1bW+vv4qm0QX5LGJlFosiLt7bnIGcZ+bFAEvwbu7TS/hpf6leapaaQLbX7UPezWZuW8vy3LxqFVj8wBHYepGa09A8V/Dq+1HS9QurmHRoNN8Q3l99ik015fPtpSPLGUBAC/3ecZwAeM8tovwi1ZtSs2uNSt7G4i01dUu1aDzHtleQpGu3OGduvUADnPSuF8f+HpfC/ia80yW/tdQ8ray3NuflkV1DDj+EjOCOxz2FLW49LHrFt488MRS2M0d3BNNZ+EruxhEtk0ipemR2iXayEd15I29ie1WPEfxJ8L6vo+r29/La3kc1tpFwkCaf5TT3SSL9s+cRj5igZck4I4XPSvCbKwvb1cWVnc3OAR+6iZ/5Z9RW7a+APGMiB4/C2tCI9XksZEQn03EYz7UxHst5478F3HiXQZrvULTUbaHxBJexzLprRrp2nGMhbVl2Zf5ivChl+XOeaz9F+IPhrUF8NXXiLVo7XV9PfUkE9vYeWERgv2dXMcR/d/e+4Cy+3WvMovAeviM/aF0y0fdu/wBL1W1gznA/jlHv/Smx+DWjhlS68R+GbdRgsftpmI5/6ZK9AHqni34ieF4l8SahoNzpkuuXWk6WlvIdMMiPdxzEzkLNGRkJg7n68YJIqh4i1fTl+BOkaxJYQxeJtajGirL5agNb28zM8y4H3jlIy3XrXmy+HNAVv9I8a6fKep+x2V1J/wCjI46X7F4KgKCTW9fu34OyLSYo159Ga4J/8d79+4ByZyxLHPvx/n2qzb289/Pb2trE81xPKEiijUszu2AFA9SePeujS48DRlFOm+I7rB+82ow24/IQPx7ZH1FbnhDxP4X0rxhoV4PDKQxWmoW8rTzX8kjRBZFJf5QikjGeRjjpQBwusabqWjy/YtWsbmzmzu8u5haN+mOhGaWyc7VIUARZbLAkevT8f89vsz4q/HjwJpttcadDa2/iu5XgwKivbA/7UjAg/wDAQ3pkV8ha34gXVdfk1S30rT9LiJO2zsIzHEo74yTzg9R+Q6UAV0uXWJI7oDY4JVgOV5PX/Pv71aQyLZhZp0RBFgoDySD39azZ7iJjcoAdnBQ9GByP8D/Oo5pJWkEjqAQDtxzkk4/xoAWUyvjMnyopVeuQo4B/z/8AWquTvy3Vu654IApVciXOVG3PPbrSSqUY9x/In27UAK6gSndg4/hB9e1RMMBcnt+VOIDuTkAYzzQZG8vyw3ynBI7Z5/xNADKKKKAJF3sowQdqnA7gd/60qAv8igDdjntwKfZf60/7tMtf9ev4/wAqAGr5hjLDO1ep/L/61SR42OEOM4OCee//ANY01f8AUN+P81qKgB5GV5zuztGKcMyAl+EyTnsDj/61Sx/68f77/wAqrj/VN/vD+tAErSHIVkDFMj279qgBwD705Puyf7v9RQP9U3+8P60APQsVZsAhOevTtV3TNSvdJ1Ow1Wwna3vrWVZYZRjKspBDYIweexBB96pQdv8AfX+tPn/1S/7q/wBaAOwtfiN4uTU9Wvk1RXvNWZTdvJbRSpMUOVYoyFRt/hIAK9sVU1Px34n1R3F5qbu39pf2vvWGNG+17AokG1QQdqKNo44zjNYNj/yz/wBx6gT/AFQ/3f8A4qgDqZfiP4qk8S3niJ9VZtVvoxBcyNDGySxhVGxoivllcAcFcZGawNc1a912/e+1B0kupAqnyoEiQBRgAIgCjgDoBWeP9U3+8P60+P8A1E34fzoA128VeIUs7eyXW9VS1t0EccAvJNiKOQAucAc9O1ZtzLLOwleV5nKgFnJYj2pv8U3+8f5NUI/1Tf7w/rQAudpJKkEnj9aFbbj7wB688EU6fv8A77f0ouP+Wf8AuCgBHwHbap2qcEjj/P40xTtORjI6VIv+ob8f5rUVADsZyyjoemM4qSbaOgwGAYD0p0X/AB7n/eP/AKCaE/48pP8Ae/woAjwTKQ6nPpSvnLoFxgkcf59qeOjf7o/9ANO/+M0AIrB2LKBgn5vf0qIuSAmCVzkKT3xTR/qm/wB4f1ptAEioSGDdjtAz0P8AnNJESG9h8x/CnN9+f8f5imJ92T/d/qKAHxgk+YoJVOSM9Ka+CMqAMHBwf8altv8AVT/7v+NV6ACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The continuous wave Doppler shows a peak systolic velocity across the pulmonary valve of 4.5 m/sec or a gradient of 81 mmHg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_14_12527=[""].join("\n");
var outline_f12_14_12527=null;
